SLEEPJEPA: LEARNING THE LATENT WORLD OF SLEEP WITH AT-HOME SLEEP DATA TO ESTIMATE DISEASE RISK

Benjamin Fox[1], **Joy Jiang**[1], **Dung T. Hoang**[1], **Elizabeth Brush**[2], **Pavel Boulgakov**[2], **Sajila Wickramaratne**[2], **Ankit Sakhuja**[1], **Oren Cohen**[2], **Mayte Suarez-Farinas**[3], **Neomi A Shah**[2], **Ankit Parekh**[*2], **and Girish N Nadkarni**[*1]

[1]The Windreich Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, NY

[2]Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

[3]Center for Biostatistics, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY

ABSTRACT

Sleep disturbances are associated with cardiovascular (CV), metabolic, and neurological diseases. While in-lab polysomnography (PSG) is the gold standard for measuring sleep disturbances, at-home PSG (hPSG) are more cost-effective, less resource intensive, and have been extensively used in large-scale epidemiological studies. Further, hPSG devices that record EEG, EOG, and EMG are developing rapidly and collect a similar wealth of information to attended in-lab PSG. However, the link between hPSG measurements and future disease risk is not well understood. We present SleepJEPA, a foundational sleep study representation model trained via a joint embedding predictive architecture that learns full night, multichannel sleep representations using hPSGs in the latent space, uncovering a wealth of high-dimensional information that more precisely informs future health outcomes than standard clinical scoring. SleepJEPA was trained, validated, and tested with 422,035 hours of sleep signal data from 55,518 sleep studies. It accurately estimates 1- to 15-year cumulative risk using a discrete hazard loss function for 10 conditions, including angina (integrated area under the receiver operating characteristic curve at 15 years [$iAUC_{15}$] = 0.74), CV disease death ($iAUC_{15}$ = 0.81), congestive heart failure ($iAUC_{15}$ = 0.83), coronary heart disease death ($iAUC_{15}$ = 0.86), incident cognitive decline ($iAUC_{10}$ = 0.79), diabetes ($iAUC_{10}$ = 0.82), hypertension ($iAUC_{10}$ = 0.79), obstructive sleep apnea ($iAUC_5$ = 0.86), myocardial infarction ($iAUC_{15}$ = 0.82), and stroke ($iAUC_{15}$ = 0.78). We also show that these outcomes can be reliably predicted in independent cohorts, including CV disease death ($iAUC_{10}$ = 0.80), coronary heart disease death ($iAUC_{10}$ = 0.76), obstructive sleep apnea ($iAUC_5$ = 0.77), and myocardial infarction ($iAUC_{10}$ = 0.62). We report increased or matched performance as compared to recent sleep foundation models, such as SleepFM. Through correlational analyses and explainability approaches, we illustrate what features are most informative for risk at different horizons. Finally, we demonstrate SleepJEPA can effectively estimate sleep stages with high accuracy (F1 = 0.77 [95% CI: 0.76 - 0.77]), objective daytime sleepiness with modest performance (AUC = 0.64 [0.57 - 0.71]), and type 1 narcolepsy (AUC = 0.88 [0.68 - 0.97]), allowing for comprehensive labeling and disease risk assessment from hPSG signals.

Keywords artificial intelligence · cardiovascular disease · deep learning · disease risk · foundational model · JEPA · self-supervision · polysomnography · sleep staging · sleepiness · transformer

1 Introduction

Sleep disturbances are a global epidemic with deleterious effects (Canever et al., 2024; Chattu et al., 2018a,b; Lim et al., 2023; McWhorter et al., 2019; Melaku et al., 2019). During the COVID-19 pandemic, it was estimated that

---

40.49% of the global population have sleep disturbances (Jahrami et al., 2022), with an estimated 10% increase during the pandemic (Partinen et al., 2021). Sleep disorders constitute a substantial portion of these estimates, with global prevalence of insomnia, obstructive sleep apnea (OSA), and restless leg syndrome affecting 850 million, 1 billion, and 325 million, respectively (Benjafield et al., 2025, 2019; Song et al.). Further, there is evidence that sleep disturbances are increasing due to continued social and economic expectations, an aging population, smartphone use, and climate change (Canever et al., 2024; Chattu et al., 2018a; Dissing et al., 2021; Lechat et al., 2025; Minor et al., 2022). Compounding upon this issue, sleep disturbances are well known to be linked to widespread conditions such as cardiovascular (CV), metabolic, and neurological disease (Chattu et al., 2018b; Lim et al., 2023). Thus, identifying the links between sleep and disease is essential.

While in-lab polysomnography (PSG) (Type I) remains the clinical benchmark for collecting sleep data and identifying sleep problems, its reliance on manual scoring and resource-heavy infrastructure has limited its scalability (Chinoy et al., 2020; Goldstein et al., 2020; Jafari and Mohsenin, 2010; Malhotra et al.). Consequently, clinical practice has pivoted toward simplified home testing (Type III) (Braun et al., 2024a; Kundel and Shah, 2017), which, while convenient, sacrifices the rich physiological signals found in EEG, EOG, and EMG. This creates a diagnostic "blind spot" where potentially predictive markers of cardiovascular, metabolic, and neurological risk—often embedded in sleep architecture—are lost. Historically, the acquisition of high-fidelity Type II hPSG has been largely confined to research due to the technical complexity of self-application and the prohibitive cost of both the device and manual scoring. However, rapid advancements in wearable sensor technology are now making EEG, EOG, and EMG data increasingly viable in the home environment (Vitazkova et al., 2025), reducing barriers to accessing a sleep study while maintaining accuracy compared to in-lab studies (Braun et al., 2024b; Korkalainen et al., 2021). Despite these advances, the link between sleep problems measured using hPSG and risk for future disease is not well established due to the complexity and size of sleep study signals, reliance on standard or aggregated PSG metrics, and studies focusing on either in-lab PSG signals or an expanded set that is not generalizable to hPSG.

Artificial intelligence (AI) could help reveal a link between sleep study signals and disease risk. Traditionally, AI approaches in sleep have assisted in labeling tasks including sleep staging and respiratory events (Lee et al., 2025; Nasiri et al., 2025; Nassi et al., 2022; Olesen et al., 2021; Perslev et al., 2021; Phan et al., 2023, 2022a,b; Zan and Yildiz, 2023), with the goal of reducing variability in scoring and removing access bottlenecks to trained sleep professionals (Nasiri et al., 2025). To better understand the relationship between sleep and future risk for disease, research has also shown that signal features extracted from sleep studies with AI algorithms can estimate CV disease and mortality risk (Ambale-Venkatesh et al., 2017; Butler et al., 2019; Cavaillès et al., 2025; Koscova et al., 2024; Zhang et al., 2020), cognitive impairment (Cavaillès et al., 2025; Haghayegh et al., 2025; Sun et al., 2025), age (Brink-Kjaer et al., 2022), and narcolepsy (Stephansen et al., 2018). However, these works utilize single modality or aggregated sleep study signal features. This could limit the vast data streams of the polysomnogram, where potentially subtle features or dynamics across multiple channels could be predictive of long-term disease risk, such as in the EEG (Lechat et al., 2022a,b). Also, these studies primarily assess performance on single cohort datasets, which limits interpretations for out-of-distribution performance. Finally, models focus on single outcomes for prediction using supervised techniques, despite the multitude of risks associated with sleep disturbances.

Recent advances in deep learning, especially self-supervision, have shown promise in learning from vast health data, including images and text for multi-outcome risk estimation with impressive performance on out-of-distribution data (Christensen et al., 2024; Huang et al., 2023; Ma et al., 2025; Xiang et al., 2025; Xu et al., 2024; Zhang et al., 2024; Zhou et al., 2023). In the sleep domain, recent works have built self-supervised models on raw polysomnogram data for sleep staging prediction and disease risk estimation (Banville et al., 2021; Fox et al., 2025a; He et al., 2025; Ogg and Coon, 2024; Thapa et al., 2026; Weng et al., 2025). However, training techniques for sleep foundational models lag vision models and typically rely on masked autoencoding or contrastive learning. Newer methods, such as joint embedding predictive architectures (JEPA) that learn representations in the latent space via predicting masked inputs from context input, could reduce learning signal channel noise and increase learning of physiological states during pretraining, compared to masked autoencoding or contrastive learning (Assran et al., 2023; Kim, 2024; Weimann and Conrad, 2025).

Here we propose SleepJEPA, the first JEPA sleep signal representation model, that learns features of multichannel, variable length (6-12 hours) hPSG signal channels, providing a scalable framework for identifying systemic disease risk. Our goals for this work were to (1) build a JEPA signal model with full night (6-12 hour) hPSG data, (2) show that full night representations contain meaningful features of sleep physiology by finetuning to sleep staging, daytime sleepiness, and age prediction tasks, (3) examine representation performance on estimating long-term (up to 15 year) disease risk, including CV, metabolic, and neurological conditions on held-out and independent test sets, and (4) identify clinically meaningful features underlying risk estimation results.

2 Methods

2.1 SleepJEPA Architecture

JEPA is a self-supervised training framework that learns representations via three key networks – a context encoder, target encoder, and predictor. First, randomly selected tokens of input data (or patches of signal data) are selected as targets (e.g., what the model will "predict" during self-supervised training). The remaining tokens (or a subset of them) are used as context (e.g., the initial input to the self-supervised model). Second, context tokens are passed through the context encoder network to create context embeddings. Learnable mask tokens are appended to the context to specify which targets to predict. These embeddings are then processed through a smaller predictor network. Third, the target embeddings are generated by passing the full, non-masked sample through the target encoder, which is a copy of the context encoder with exponentially weighted moving average weight adjustments. The target embeddings are then subset to the originally selected targets and compared to the predictor's output via a regression loss function. This embedding space prediction is hypothesized to learn more semantic representations (Assran et al., 2023), while also reducing noisy reconstructions and representational collapse (Jing et al., 2022).

SleepJEPA incorporates long signal data from sleep studies. It aims to reduce learning signal noise common with masked autoencoding self-supervised learning approaches and focus on learning representations of the physiological state of sleep in the latent space. Previous works demonstrated that the JEPA architecture with signal data improves performance over other self-supervised approaches in ECG classification (Kim, 2024; Weimann and Conrad, 2025), wearables (Xie et al., 2025), and ICU risk prediction (Fox et al., 2025b). SleepJEPA is based on the PhysioJEPA architecture published by our group (Fox et al., 2025b), which utilizes patch time series transformers (Nie et al., 2023) as the context, target, and predictor networks. An overview of the context encoder, target encoder, and predictor are detailed in Extended Data Figures 1, 2, and 3. SleepJEPA uses signals from seven signal channels, including a single EEG channel (C4-M1 or C3-M2), left EOG (E1-M2), chin EMG, augmented lead II ECG, SpO2, respiratory inductance plethysmography (RIP) signals across the thorax and abdomen, of any length (6 to 12 hours) to accommodate varying length sleep studies. For datasets, preprocessing, and model architecture specifics, see the Supplementary Methods.

2.1.1 Self-Supervised Training Monitoring

During self-supervised learning, it is difficult to assess when representations are robust and have avoided dimensional or complete collapse. This is a notable problem in contrastive learning approaches (Jing et al., 2022; Tian et al., 2021) and JEPA architectures (Assran et al., 2023; Balestriero and LeCun, 2025). Thus, our model's linear probing capabilities were evaluated with a validation set from the pretraining data at the end of every pretraining epoch. A logistic regression with 5-fold cross validation was fit to estimate sleep stages, including wake, stage 1 (N1), stage 2 (N2), stage 3 (N3), and rapid eye movement (REM) sleep. The pretraining epoch with the best performance was selected for finetuning of all downstream tasks.

2.1.2 Assessing Representations

After representation learning, finetuning heads were trained with frozen representations to estimate sleep stages, age, and daytime sleepiness to assess representation features and their associations with outcomes and labels. For sleep staging, a 2-layer bidirectional gated recurrent unit (GRU) was utilized as previously described (Fox et al., 2025a). See the Supplementary Methods for datasets, preprocessing, and model architecture specifics.

Age was estimated using an attentive regression model. See Extended Data Figure 4 for an illustration and the Supplementary Methods for training specifics.

Finally, to assess daytime sleepiness, the overnight PSG from the preceding night of a mean sleep latency test (MSLT) was utilized to estimate an MSLT score of less than or equal to 8 minutes, an indicator for objective daytime sleepiness (Goldbart et al., 2014). Additionally, narcolepsy outcomes were also used to train an additional model to estimate type 1 narcolepsy. Narcolepsy labels reflect mean sleep latency of less than or equal to 8 minutes and presence of at least 2 sleep onset REM periods (REM latency of less than or equal to 15 minutes in at least 2 naps) (Stephansen et al., 2018). For both daytime sleepiness outcomes, an attentive classifier head was utilized. Additional training details are provided in the Supplementary Methods.

2.2 Estimating Long-term Disease Risk

Ten outcomes spanning CV, metabolic, and neurological conditions were evaluated. Independent finetuning heads were trained per outcome. Details on the datasets and outcome processing are provided in the Supplementary Methods.

To estimate long-term disease risk, an attentive classifier was trained using a discrete hazard loss function. Discrete hazard loss functions estimate risk at multiple discrete times, handle non-proportional hazards, and optimize training in comparison to other hazard functions (Gensheimer and Narasimhan, 2019). Traditionally, Cox proportional hazard models are employed to estimate risk at a single time point in machine learning settings (Ching et al., 2018; Katzman et al., 2018; Thapa et al., 2026). Yet, in clinical scenarios, the proportional hazards assumption is more than likely violated as observation effects vary across time. Further, when training with Cox proportional hazard models, each sample's estimated risk depends on all other samples' risks that survived longer. Thus, when using gradient descent, the batch size influences the risk estimates, since individual batch-samples' risks are only being compared to other batch samples and not all other samples in the training dataset. The discrete hazard loss function does not have this issue.

We explored three models per outcome: a model that utilizes only sleep representations (SleepJEPA), a model that includes age and sex hazards modeling with sleep representations (SleepJEPA+), and a baseline demographics (age and sex) only model. The third model is to elucidate the effects of demographic variables on predictions over time and better assess the performance of our sleep representations. See the Supplementary Methods for additional details on model architectures.

2.3 Model Evaluation

Models were evaluated with standard metrics depending on the task. Sleep stages were evaluated with area under the receiver operating characteristics curve (AUC), Cohen's Kappa, F1, confusion matrices, and accuracy. Age estimation was assessed with mean absolute error and Pearson's correlation coefficient. Daytime sleepiness was assessed with AUC, area under the precision recall curve (AUPRC), recall, and specificity. 95

For long-term disease outcomes, the cumulative/dynamic AUC (C/D AUC) score was used to assess performance at specific risk horizons (Lambert and Chevret, 2016). This score was also integrated (iAUC) to assess performance of previous risk horizons up to the current and serves as an aggregated metric of C/D AUC. Additionally, to assess calibration and discrimination, the integrated Brier score (IBS) was used to measure the model's performance across all risk horizons. The IBS calculates the inverse probability of censoring weights (IPCW) to estimate the censoring distribution of the training dataset, providing a more reliable population estimate (Graf et al., 1999). Finally, the IPCW concordance index (C-Index) was used to evaluate performance at specific risk horizons (Uno et al., 2011). Again, the IPCW C-Index relies on the training dataset censoring distribution and provides a more reliable estimate, compared to using the testing dataset censoring distribution.

2.4 Clinical Interpretation

To better understand the predicted risk scores, the Pearson correlation between the predicted risk score with demographic and baseline polysomnogram derived features, including age, ESS, BMI, stage 1, 2, 3, REM, and overall sleep time, sleep efficiency, average SpO2, minimum SpO2, obstructive apnea hypopnea index (AHI), and central AHI, were calculated at 1, 2, 3, 5, 10, and 15 year horizons. Correlations are illustrated in clustered heatmaps to show features associated with risk predictions at different risk horizons and in box plots to show average correlation across all risk horizons. Additionally, survival curves were plotted to better understand the estimated predicted risk across quartiles for outcomes in both the held-out and independent test sets. Platt scaling was performed for calibration using the validation set for each model-outcome.

2.5 Model Explainability

The integrated gradients method (Sundararajan et al., 2017) was implemented to better understand representations in relation to estimating long-term disease risk. This method helps attribute an importance value to channel representations. Attributions for each 3-second patch were computed for each outcome to identify patches of signals and signal channels contributing to risk prediction results for outcomes from held-out test sets. Additional details regarding this method are described in the Supplementary Methods.

3 Results

SleepJEPA was pretrained with 34,291 sleep studies (n = 27,067 unique patients) and finetuned on 21,227 separate sleep studies (n = 18,839 unique patients). In total, our model was trained, validated, and tested on 422,035 hours of sleep study data with 7 signal channels. Demographics of the datasets used in pretraining and finetuning are reported in Table 1. The median age of our pretraining dataset was 55 (interquartile range [IQR]: 43 - 66), median BMI was 30.1 (26.0 - 35.5), median Epworth Sleepiness Score (ESS) was 8 (4 - 12), and 44.6% were female. The finetuning cohort

Figure 1: SleepJEPA Overview. Full night (6-12 hour) hPSG data from 7 channels are tokenized into 3 second patches and passed through SleepJEPA to generate representations. Representations are used as input to train additional models including sleep staging, long-term disease risk, and sleep study specific outcomes.

	n Studies	n Patients	Median Age (IQR)	Sex, % Female	Race, % White	Median BMI (IQR)	Median ESS (IQR)	Median AHI (IQR)	Collection Period	Split
Human Sleep Project	22870	17697	55 (43-66)	43.03%	-	30.38 (26.23-35.77)	8 (4-12)	-	2007-2023	Pretrain
Mount Sinai PSG	6728	6123	54 (40-65)	50.71%	37.22%	29.53 (25.34–35.26)	6 (1-11)	-	2017-2024	Pretrain
SHHS Visit 1	5755	5755	63 (55-72)	52.38%	84.57%	27.49 (24.67-30.76)	7 (4-11)	13.21 (6.69-23.78)	1995-1998	Finetune
MrOS Visit 1	2898	2898	76 (72-80)	0.00%	90.72%	26.72 (24.56-29.33)	6 (3-8)	17.10 (9.09-29.49)	2005	Finetune
SHHS Visit 2	2608	2608	67 (60-76)	53.64%	87.23%	27.71 (24.86-31.13)	7 (4-10)	13.53 (6.73-24.50)	2001-2003	Finetune
WSC	2522	1116	60 (54-66)	46.39%	95.84%	30.30 (26.52-35.30)	8 (5-11)	14.20 (6.20-27.48)	2000–2015	Pretrain/Finetune
MESA	2054	2054	68 (62-76)	53.65%	36.17%	27.88 (24.63-31.83)	5 (3-8)	18.36 (9.49-33.23)	2010–2012	Finetune
MNC	498	498	-	-	-	-	-	-	-	Pretrain/Finetune
APPLES	1055	1055	52 (43-61)	34.60%	76.30%	30.62 (27.09-36.11)	10 (7-13)	34.20 (19.80-53.80)	2003–2008	Pretrain
MrOS Visit 2	996	996	80 (77-84)	0.00%	87.35%	27.00 (24.00-29.00)	6 (4-9)	17.00 (9.00-31.00)	2009–2012	Finetune

Table 1: Sleep Study Demographics, if available. MNC does not provide any demographic information. Apnea hypopnea index (AHI) represents all apneas independent of arousal and hypopneas with > 30% flow reduction and >= 3% oxygen desaturation or with arousal. ESS: Epworth Sleepiness Score.

had a median age of 68 (58 - 75), a median BMI of 27.7 (24.9 - 31.4), a median ESS of 7 (4 - 10), and 40.0% were female. An overview of the SleepJEPA design is in Figure 1.

After 16 epochs, SleepJEPA reached the best performance, based on the AUC score on sleep stage linear probing. Training loss decreased and validation AUC increased up to this point, after which training loss dropped substantially while validation AUC began to plateau. While validation sleep stage AUC scores were optimal (> 0.70) at lower training losses, epoch 16 was chosen as it provides the best linearly separable representations and could help avoid representational collapse in later epochs. See Supplementary Figure 1 for training loss and validation AUC curves.

3.1 SleepJEPA Performance in Sleep Staging

Sleep staging distributions are available in Supplementary Table 1. On a held-out test set of 2,531 sleep studies, SleepJEPA representations achieved a macro-AUC of 0.97 (95% CI: 0.97 - 0.97), with a Cohen's Kappa of 0.80 (0.80 - 0.81), a macro F1 score of 0.77 (0.76 - 0.77), and a micro accuracy of 0.86 (0.86 - 0.86). The model was independently tested on 4,050 sleep studies, reaching a macro-AUC score of 0.92 (95% CI: 0.91 - 0.92), Cohen's Kappa was 0.66 (0.65 - 0.66), macro F1 was 0.61 (0.61 - 0.62), and micro accuracy was 0.77 (0.77 - 0.77). Confusion matrices are reported in Figure 2.

Compared to other state-of-the-art sleep staging models, SleepJEPA performs comparably. L-SeqSleepNet (Phan et al., 2023), SleepTransformer (Phan et al., 2022a), XSleepNet (Phan et al., 2022b), USleep (Perslev et al., 2021), FullSleepNet (Zan and Yildiz, 2023), and SleepXViT (Lee et al., 2025) had the highest performance based on macro F1 scores on the Sleep Heart Health Study (SHHS) (macro F1 = 80.0-81.0), compared to SleepJEPA (77.2). However, these models were all trained end-to-end for the sleep staging task. On the Osteoporotic Fractures in Men Study (MrOS), USleep and SleepFM (Thapa et al., 2026) achieved the highest macro F1 scores on a held-out test set, reaching 77.0 for USleep and 75.0 for SleepFM. SleepJEPA achieved a macro F1 score of 74.3 on only MrOS Visit 1, with fewer signal channels. On the Wisconsin Sleep Cohort (WSC), SleepJEPA and PFTSleep (Fox et al., 2025a) achieve the highest performance with 74.7 and 73.8 macro F1 scores, respectively.

On independent testing sets, SleepJEPA was compared to PFTSleep, a patch foundational transformer model trained via a masked autoencoder framework that similarly learn representations to finetune for sleep staging. SleepJEPA modestly outperforms PFTSleep across the MrOS Visit 2, the Multi-Ethnic Study of Atherosclerosis (MESA), and the Apnea

Figure 2: SleepJEPA Sleep Stage Confusion Matrices. Row normalized confusion matrices (with counts) for sleep stage classification on held-out test sets SHHS Visit 1, SHHS Visit 2, MrOS Visit 1, and WSC (top row) and independent test sets MrOS Visit 2, MESA, and APPLES (bottom row).

Dataset	Model	Micro Accuracy	Cohen's Kappa	Macro F1	F1 (W)	F1 (N1)	F1 (N2)	F1 (N3)	F1 (REM)
SHHS	SleepJEPA	85.98	0.8	77.21	92.87	41.45	85.84	76.29	89.65
	SleepFM (Thapa et al., 2026)	-	-	78	92	49	84	72	**91**
	PFTSleep (Fox et al., 2025a)	86.07	0.8	76.53	92.17	35.92	86.47	78.27	89.82
	SleepXViT (Visit 1) (Lee et al., 2025)	**88.07**	**0.83**	80.18	**93.29**	45.34	**88.57**	83.5	90.18
	L-SeqSleepNet (Phan et al., 2023)	87.6	**0.83**	80.3	92.4	48.6	88.2	83.9	88.5
	SeqSleepNet (Phan et al., 2019)	87.2	**0.82**	80.2	91.8	49.1	88.2	83.5	88.2
	SleepTransformer (Phan et al., 2022a)	**87.7**	**0.83**	80.1	92.2	46.1	88.3	**85.2**	88.6
	XSleepNet1 (Phan et al., 2022b)	87.6	**0.83**	**80.7**	91.6	**51.4**	**88.5**	85	88.4
	XSleepNet2 (Phan et al., 2022b)	87.5	**0.83**	**81**	92	49.9	88.3	85	88.2
	U-Sleep (Perslev et al., 2021)	-	-	**80**	93	**51**	87	76	**92**
	FullSleepNet (Zan and Yildiz, 2023)	87.55	**0.83**	80.3	92.8	48.5	88	82.4	89.8
	Olesen et al. (Olesen et al., 2021)	87.1	**0.82**	78.8	**94.1**	47.8	87.9	74.3	89.9
	AttnSleep (Eldele et al., 2021)	84.2	0.78	75.3	**86.7**	33.2	87.1	**87.1**	82.1
MrOS	SleepJEPA (Visit 1)	**87.25**	**0.81**	74.26	**94.45**	36.6	86.27	65.87	88.13
	SleepFM (Thapa et al., 2026)	-	-	75	94	41	86	65	**90**
	PFTSleep (Visit 1) (Fox et al., 2025a)	**87.96**	**0.82**	72.57	**95.03**	23.1	**86.76**	**69.65**	**88.31**
	Olesen et al. (Olesen et al., 2021)	**84.3**	0.76	-	-	-	-	-	-
	USleep (Perslev et al., 2021)	-	-	**77**	93	**46**	**87**	**68**	88
WSC	SleepJEPA	**85.07**	0.77	**74.65**	88.74	**47.57**	90.17	**56.14**	**90.61**
	PFTSleep (Fox et al., 2025a)	**85.47**	**0.78**	**73.77**	**90.03**	33.83	90.05	**65.24**	89.69
	Olesen et al. (Olesen et al., 2021)	**82.6**	**0.72**	-	-	-	-	-	-
	Olesen et al. 2018 (Olesen et al., 2018)	85	0.75	72.6	**88.8**	**49.7**	**90.2**	47.3	87.2
MrOS Visit 2*	SleepJEPA	**84.86**	**0.76**	**69.41**	93.6	**28.83**	81.99	57.97	**84.66**
	PFTSleep (Fox et al., 2025a)	84.36	0.75	66.72	92.86	13	81.93	**61.56**	84..22
MESA*	SleepJEPA	**75.18**	**0.63**	**57.2**	**87.44**	**13.66**	74.44	38.59	71.87
	PFTSleep (Fox et al., 2025a)	72.72	0.6	56.73	79.79	3.11	**76.03**	**47.34**	**77.39**
APPLES*	SleepJEPA	71.42	0.59	**60.1**	81.23	**24.65**	**76.9**	**32.91**	84.81
	PFTSleep (Fox et al., 2025a)	**71.79**	0.59	58.47	**84.59**	11.83	76.12	32.42	**87.38**

Table 2: Sleep Stage Predictive Performance Comparison. Table adapted from Phan et al. (Phan et al., 2023) and Fox et al. (Fox et al., 2025a). Bold, underlined indicates best performance and bold only indicates second best performance. Performance was calculated on held-out test data for SHHS, MrOS, and WSC. Test sets were not identical. * Indicates the datasets are independent test sets.

Positive Pressure Long-term Efficacy Study (APPLES) test sets, reaching macro F1 scores of 69.4, 57.2, and 60.10, compared to PFTSleep's scores of 66.7, 56.7, and 58.5, respectively. Additional results comparing models by dataset are reported in Table 2.

3.2 Association of SleepJEPA with Chronological Age

To understand the relationship between SleepJEPA's representations and age, an attentive regression model was trained to predict chronological age. On the held-out test set of 1,728 studies, comprising MrOS Visit 1 and SHHS Visit 1 cohorts, mean absolute error (MAE) was 5.51, and the Pearson correlation was 0.80. For our independent test set on 4,576 studies, comprising MESA and WSC cohorts, the MAE was 6.47, and Pearson correlation was 0.61. MAE by

Figure 3: SleepJEPA Age Predictive Performance. Smoothed mean absolute error by age with 95% bootstrapped confidence intervals (n = 999 resamples) for the held-out test (left) and independent test set (right).

Outcomes	Test Set	AUC	Average Precision	Recall	Specificity
Objective Daytime Sleepiness	Held-Out	0.64 (0.57 - 0.71)	0.36 (0.26 - 0.44)	0.70 (0.60 - 0.80)	0.50 (0.43 - 0.56)
	Independent (MNC, Type 1 Narcolepsy)	0.65 (0.58 - 0.73)	0.14 (0.09 - 0.19)	0.36 (0.23 - 0.51)	0.78 (0.75 - 0.82)
Type 1 Narcolepsy	Held-Out	0.88 (0.68 - 0.97)	0.53 (0.15 - 0.79)	0.30 (0.08 - 0.75)	0.98 (0.92 - 1.00)
	Independent (WSC, MSLT <= 8)	0.56 (0.52 - 0.59)	0.30 (0.26 - 0.34)	0.00 (0.00 - 0.01)	0.99 (0.99 - 1.00)

Table 3: SleepJEPA Daytime Sleepiness Outcomes Predictive Performance. SleepJEPA was trained to estimate type 1 narcolepsy with the MNC cohort and objective daytime sleepiness (MSLT <= 8) on the WSC cohort. Each model was then used to estimate the other's outcome as an independent test. Performance metrics are shown above for the held-out test sets (same dataset as training) and independent test set for both models. 95% bootstrapped confidence intervals (n = 999 resamples) are reported.

age is shown in Figure 3 and depicts performance across ages, related to the distribution of the test sets. Generally, SleepJEPA performs the best at predicting age for those in the 55-70 range, while younger and older predictions become more variable. Predicted vs actual age plots are shown in Supplementary Figure 2 for both the held-out and independent test sets.

3.3 Association of SleepJEPA with Daytime Sleepiness

To assess objective daytime sleepiness and type 1 narcolepsy status, two additional attentive classifiers were trained for each outcome. Outcome distributions are reported in Supplementary Table 2. For type 1 narcolepsy prediction, SleepJEPA representations reached an AUC score of 0.88 (95% CI: 0.68 - 0.97) and AUPRC of 0.53 (0.15 - 0.79) compared to the positive prevalence of 8.8%. When independently testing the MSLT outcomes from WSC, the model had reduced performance (AUC = 0.56 [0.52 - 0.59] and AUPRC = 0.30 [0.26 - 0.34]). When predicting objective daytime sleepiness based on MSLT scores, SleepJEPA AUC scores were 0.64 (0.57 - 0.71), with an AUPRC of 0.36 (0.26 - 0.44) compared to the positive prevalence of 25.4%. When independently testing the Mignot Nature Communications (MNC) narcolepsy outcomes, AUC was 0.65 (0.58 - 0.73), and AUPRC was 0.14 (0.09 - 0.19). Additional metrics are reported in Table 3.

Outcome	Year	iAUC SleepJEPA+	SleepJEPA	Age+Sex	C/D AUC SleepJEPA+	SleepJEPA	Age+Sex	C-Index SleepJEPA+	SleepJEPA	Age+Sex
Angina	1	0.69	**0.71**	**0.69**	0.69 (0.58-0.80)	**0.71 (0.56-0.80)**	0.69 (0.57-0.86)	0.69 (0.63-0.74)	**0.71 (0.65-0.76)**	**0.69 (0.63-0.75)**
	2	**0.68**	**0.69**	0.66	**0.68 (0.61-0.75)**	**0.68 (0.59-0.75)**	0.65 (0.58-0.73)	**0.67 (0.61-0.73)**	**0.67 (0.61-0.73)**	0.64 (0.58-0.70)
	3	**0.68**	**0.68**	0.66	**0.68 (0.62-0.74)**	0.65 (0.57-0.72)	**0.67 (0.62-0.73)**	**0.67 (0.61-0.73)**	0.64 (0.58-0.70)	**0.66 (0.59-0.72)**
	5	**0.69**	0.67	**0.69**	0.72 (0.68-0.77)	0.65 (0.58-0.70)	**0.75 (0.71-0.79)**	0.68 (0.60-0.75)	0.62 (0.54-0.70)	**0.71 (0.63-0.78)**
	10	**0.71**	0.67	**0.71**	**0.79 (0.75-0.83)**	0.68 (0.63-0.73)	**0.79 (0.75-0.83)**	**0.72 (0.63-0.80)**	0.65 (0.55-0.73)	**0.72 (0.62-0.80)**
	15	**0.74**	0.68	**0.74**	**0.87 (0.71-1.00)**	0.66 (0.16-0.78)	**0.92 (0.82-1.00)**	0.72 (0.48-0.87)	0.65 (0.42-0.83)	**0.73 (0.49-0.88)**
Cardiovascular Disease Death	1	**0.9**	**0.92**	0.71	**0.90 (0.68-0.93)**	**0.92 (0.82-0.94)**	0.71 (0.56-0.76)	**0.90 (0.84-0.93)**	**0.91 (0.86-0.95)**	0.71 (0.63-0.77)
	2	**0.81**	0.75	0.76	**0.77 (0.64-0.87)**	0.68 (0.55-0.84)	**0.79 (0.68-0.85)**	**0.77 (0.71-0.82)**	0.68 (0.62-0.74)	**0.78 (0.73-0.83)**
	3	**0.81**	0.75	**0.77**	**0.81 (0.70-0.89)**	0.72 (0.60-0.83)	**0.81 (0.72-0.86)**	**0.80 (0.74-0.85)**	0.71 (0.64-0.77)	**0.80 (0.74-0.85)**
	5	**0.82**	0.73	**0.8**	**0.82 (0.77-0.87)**	0.72 (0.65-0.79)	**0.83 (0.78-0.86)**	**0.81 (0.75-0.86)**	0.71 (0.64-0.77)	**0.82 (0.76-0.86)**
	10	**0.84**	0.76	**0.84**	**0.88 (0.85-0.91)**	0.80 (0.76-0.84)	**0.87 (0.84-0.90)**	**0.85 (0.79-0.89)**	0.77 (0.71-0.83)	**0.84 (0.78-0.89)**
	15	**0.81**	0.68	**0.82**	0.74 (0.68-0.79)	0.54 (0.47-0.61)	**0.77 (0.70-0.83)**	0.79 (0.69-0.87)	0.68 (0.57-0.77)	**0.80 (0.70-0.88)**
Congestive Heart Failure	1	**0.76**	**0.76**	0.75	**0.76 (0.65-0.91)**	**0.76 (0.64-0.91)**	0.75 (0.58-0.83)	**0.76 (0.71-0.80)**	**0.76 (0.71-0.80)**	0.75 (0.70-0.79)
	2	**0.81**	0.78	0.74	**0.83 (0.77-0.88)**	0.79 (0.71-0.86)	0.74 (0.67-0.79)	**0.82 (0.77-0.86)**	**0.78 (0.73-0.82)**	0.73 (0.68-0.78)
	3	**0.81**	0.78	0.74	**0.83 (0.78-0.88)**	0.78 (0.71-0.84)	0.75 (0.69-0.80)	**0.82 (0.76-0.86)**	**0.77 (0.71-0.82)**	0.74 (0.68-0.79)
	5	**0.8**	0.75	**0.76**	**0.80 (0.76-0.84)**	0.73 (0.67-0.78)	**0.78 (0.74-0.82)**	**0.78 (0.71-0.83)**	0.71 (0.64-0.77)	**0.74 (0.67-0.80)**
	10	**0.81**	0.75	**0.77**	**0.81 (0.77-0.84)**	0.73 (0.68-0.77)	**0.76 (0.73-0.79)**	**0.77 (0.70-0.82)**	0.71 (0.64-0.77)	**0.71 (0.64-0.77)**
	15	**0.83**	0.76	**0.8**	**0.98 (0.94-1.00)**	0.75 (0.54-0.89)	**0.96 (0.89-1.00)**	**0.78 (0.61-0.89)**	0.71 (0.54-0.84)	**0.74 (0.57-0.87)**
Coronary Heart Disease Death	1	**0.93**	**0.85**	0.49	**0.93 (0.79-0.96)**	**0.85 (0.60-0.91)**	0.49 (0.22-0.76)	**0.93 (0.86-0.96)**	**0.85 (0.77-0.91)**	0.49 (0.39-0.59)
	2	**0.82**	**0.72**	0.6	**0.77 (0.61-0.91)**	**0.65 (0.46-0.84)**	0.65 (0.41-0.80)	**0.77 (0.69-0.83)**	**0.65 (0.57-0.73)**	0.65 (0.56-0.73)
	3	**0.82**	**0.72**	0.6	**0.79 (0.63-0.92)**	**0.73 (0.57-0.87)**	0.61 (0.39-0.77)	**0.79 (0.71-0.85)**	**0.72 (0.64-0.80)**	0.60 (0.51-0.70)
	5	**0.82**	**0.74**	0.57	**0.85 (0.75-0.93)**	**0.77 (0.64-0.87)**	0.69 (0.52-0.81)	**0.84 (0.76-0.90)**	**0.77 (0.68-0.84)**	0.69 (0.59-0.77)
	10	**0.86**	**0.77**	0.64	**0.89 (0.83-0.94)**	0.79 (0.70-0.86)	0.79 (0.70-0.86)	**0.87 (0.78-0.93)**	0.77 (0.67-0.85)	0.77 (0.66-0.86)
	15	**0.86**	**0.77**	0.68	**0.93 (0.82-0.97)**	0.86 (0.71-0.94)	**0.87 (0.73-0.94)**	**0.83 (0.43-0.97)**	0.76 (0.37-0.94)	0.76 (0.34-0.95)
Incident Cognitive Decline	1	**0.92**	**0.85**	0.82	**0.92 (0.87-1.00)**	**0.85 (0.76-1.00)**	0.82 (0.73-0.95)	**0.92 (0.82-0.96)**	**0.85 (0.73-0.92)**	0.82 (0.70-0.90)
	2	**0.8**	**0.77**	0.71	**0.75 (0.63-0.87)**	0.73 (0.59-0.88)	0.66 (0.52-0.84)	**0.74 (0.59-0.85)**	**0.72 (0.57-0.83)**	0.66 (0.51-0.78)
	3	**0.79**	**0.75**	0.7	**0.74 (0.63-0.85)**	0.66 (0.52-0.83)	0.65 (0.53-0.81)	**0.73 (0.56-0.85)**	0.66 (0.49-0.80)	0.64 (0.47-0.78)
	5	**0.78**	0.7	0.72	**0.77 (0.68-0.85)**	0.62 (0.51-0.75)	**0.74 (0.66-0.83)**	**0.73 (0.54-0.86)**	0.61 (0.43-0.77)	**0.70 (0.50-0.84)**
	10	**0.79**	0.69	0.73	**0.82 (0.73-0.89)**	0.67 (0.57-0.78)	**0.77 (0.68-0.86)**	**0.73 (0.51-0.88)**	0.63 (0.42-0.81)	**0.68 (0.46-0.84)**
Incident Diabetes	1	0.73	**1**	0.67	0.73 (0.70-0.76)	**1.00 (1.00-1.00)**	0.67 (0.64-0.70)	0.73 (0.62-0.81)	**1.00 (0.95-1.00)**	0.67 (0.56-0.76)
	2	0.83	**0.89**	0.65	**0.84 (0.75-0.89)**	**0.87 (0.77-0.95)**	0.65 (0.54-0.75)	**0.84 (0.76-0.90)**	**0.87 (0.79-0.92)**	0.65 (0.55-0.73)
	3	0.84	**0.89**	0.66	**0.87 (0.80-0.91)**	**0.90 (0.82-0.96)**	0.72 (0.61-0.81)	**0.86 (0.78-0.92)**	**0.89 (0.81-0.94)**	0.71 (0.61-0.80)
	5	0.81	**0.87**	0.68	0.74 (0.63-0.84)	**0.79 (0.69-0.90)**	0.66 (0.56-0.76)	0.72 (0.55-0.84)	**0.78 (0.62-0.89)**	0.65 (0.48-0.79)
	10	0.72	**0.82**	0.69	0.77 (0.67-0.87)	**0.77 (0.65-0.87)**	0.72 (0.60-0.83)	0.63 (0.44-0.79)	**0.64 (0.45-0.80)**	0.58 (0.39-0.75)
Incident Hypertension	2	**0.83**	0.77	0.74	**0.83 (0.77-0.91)**	0.77 (0.67-0.87)	0.74 (0.55-0.82)	**0.82 (0.72-0.89)**	**0.76 (0.66-0.84)**	0.73 (0.62-0.82)
	3	**0.77**	0.74	0.69	**0.72 (0.62-0.82)**	0.71 (0.62-0.81)	0.65 (0.52-0.75)	**0.71 (0.60-0.80)**	**0.71 (0.60-0.80)**	0.65 (0.53-0.75)
	5	**0.65**	0.63	**0.65**	**0.65 (0.58-0.73)**	0.62 (0.55-0.70)	**0.66 (0.61-0.73)**	0.64 (0.53-0.73)	0.62 (0.51-0.72)	**0.65 (0.54-0.74)**
	10	**0.78**	**0.79**	0.71	**0.84 (0.79-0.88)**	0.82 (0.76-0.87)	0.71 (0.64-0.76)	**0.70 (0.59-0.79)**	0.68 (0.57-0.77)	0.60 (0.49-0.70)
Incident OSA	5	**0.86**	0.75	0.47	**0.86 (0.72-0.90)**	0.75 (0.64-0.86)	0.47 (0.31-0.62)	**0.86 (0.72-0.93)**	0.75 (0.60-0.85)	0.47 (0.33-0.62)
Myocardial Infarction	1	**0.81**	0.67	**0.77**	**0.81 (0.72-0.86)**	0.67 (0.53-0.78)	**0.77 (0.70-0.82)**	**0.81 (0.76-0.85)**	0.66 (0.61-0.71)	**0.77 (0.72-0.82)**
	2	**0.81**	0.69	**0.77**	**0.81 (0.75-0.85)**	0.71 (0.63-0.79)	**0.77 (0.71-0.81)**	**0.80 (0.75-0.85)**	0.70 (0.64-0.76)	**0.76 (0.70-0.81)**
	3	**0.81**	0.69	**0.77**	**0.80 (0.74-0.84)**	0.68 (0.61-0.76)	**0.76 (0.70-0.80)**	**0.79 (0.73-0.83)**	0.67 (0.61-0.73)	**0.74 (0.68-0.80)**
	5	**0.8**	0.69	**0.77**	**0.78 (0.73-0.83)**	0.69 (0.63-0.75)	**0.78 (0.72-0.82)**	**0.74 (0.66-0.80)**	0.66 (0.58-0.73)	**0.74 (0.66-0.80)**
	10	**0.79**	0.68	**0.77**	**0.75 (0.70-0.79)**	0.65 (0.59-0.70)	**0.75 (0.70-0.80)**	**0.70 (0.62-0.77)**	0.62 (0.53-0.70)	**0.70 (0.62-0.78)**
	15	**0.82**	0.7	**0.8**	**0.94 (0.85-0.99)**	0.66 (0.50-0.95)	**0.94 (0.85-0.98)**	**0.74 (0.51-0.89)**	0.65 (0.42-0.83)	**0.74 (0.51-0.89)**
Stroke	1	**0.67**	0.62	**0.64**	**0.67 (0.54-0.78)**	0.62 (0.52-0.74)	**0.64 (0.55-0.76)**	**0.67 (0.61-0.71)**	0.62 (0.57-0.67)	**0.64 (0.59-0.69)**
	2	**0.71**	0.65	**0.72**	**0.74 (0.66-0.80)**	0.67 (0.59-0.73)	**0.76 (0.69-0.82)**	**0.73 (0.67-0.78)**	0.66 (0.60-0.71)	**0.75 (0.69-0.80)**
	3	**0.72**	0.65	**0.72**	**0.74 (0.67-0.80)**	0.67 (0.60-0.73)	**0.76 (0.70-0.82)**	0.73 (0.67-0.78)	0.66 (0.59-0.72)	**0.75 (0.69-0.80)**
	5	**0.74**	0.67	**0.74**	**0.80 (0.75-0.85)**	0.71 (0.64-0.77)	**0.79 (0.74-0.84)**	**0.76 (0.68-0.83)**	0.67 (0.58-0.74)	**0.75 (0.67-0.82)**
	10	**0.77**	0.68	**0.76**	**0.84 (0.80-0.88)**	0.71 (0.66-0.77)	**0.82 (0.79-0.86)**	**0.78 (0.69-0.85)**	0.66 (0.57-0.75)	**0.76 (0.67-0.83)**
	15	**0.78**	0.69	**0.78**	**0.98 (0.94-1.00)**	0.84 (0.59-0.89)	**0.98 (0.94-1.00)**	**0.79 (0.49-0.94)**	0.68 (0.39-0.88)	**0.77 (0.47-0.93)**

Table 4: SleepJEPA long-term outcomes predictive performance at different forecast lengths. SleepJEPA+, SleepJEPA, and the baseline demographics age+sex model are reported. iAUC is the integral of the C/D AUC, up to that year. C-Index is the IPCW C-Index for the reported year. Bold, underlined indicates best performance and bold indicates second best performance. Results are for the 20% held-out test set for each outcome. 95% bootstrapped confidence intervals (n = 999 resamples) are reported for C/D AUC and C-Index.

3.4 SleepJEPA Risk Estimation for Long-term Disease

SleepJEPA representations were frozen and used as input into 10 separate attentive classifiers to estimate long-term disease risk (SleepJEPA). Dataset event distributions are in Extended Data Table 1, and training, validation, and testing splits are in Supplementary Table 3. Each model was trained for 10 epochs for lightweight finetuning to disease outcomes. Additionally, a baseline demographics model (age and sex) and a SleepJEPA representations model with age and sex hazards modeling (SleepJEPA+) were trained for each outcome. Training details are provided in the Supplementary Methods. The iAUC, C/D AUC, and IPCW C-Index were calculated at 1, 2, 3, 5, 10, and 15 years and reported in Table 4. Additionally, C/D AUC curves over 15 years for all outcomes are illustrated in Figure 4.

Across nearly all time horizons and outcomes, SleepJEPA+ improved predictive performance compared to the demographics baseline. As forecasting horizons extend further from the baseline sleep study, participants are naturally older, making age an increasingly strong predictor for nearly all outcomes. Consequently, SleepJEPA+ and SleepJEPA performed better at closer horizons compared to the demographics only baseline, with top iAUC scores at 1-, 2-, and 3-year forecasts, except for stroke, where the baseline demographics model matches performance at 2- and 3-year horizons. For angina, CV disease death, and incident diabetes, SleepJEPA representations outperform the baseline demographics model and SleepJEPA+ at 1 year with iAUC scores of 0.71, 0.92, and 1.0, respectively. At two and three years, these trends persist for angina and incident diabetes with iAUC scores of 0.69 and 0.89 at year 2 and 0.68 and 0.89

Figure 4: C/D AUC plots for each outcome on the 20% held-out test sets, up to 15 years. SleepJEPA+, SleepJEPA, and the baseline demographics model are reported. 95% bootstrapped confidence intervals (n = 999 resamples) are shaded for each model.

Outcome	Dataset	Year	iAUC SleepJEPA+	SleepJEPA	Age+Sex	C/D AUC SleepJEPA+	SleepJEPA	Age+Sex	C-Index SleepJEPA+	SleepJEPA	Age+Sex
Cardiovascular Disease Death	MESA	1	**0.88**	**0.74**	0.26	**0.88 (0.87-0.89)**	**0.74 (0.72-0.76)**	0.26 (0.25-0.27)	**0.88 (0.83-0.92)**	**0.74 (0.67-0.79)**	0.26 (0.19-0.35)
		2	**0.85**	0.62	**0.62**	**0.85 (0.79-0.90)**	0.60 (0.47-0.80)	**0.66 (0.45-0.77)**	**0.85 (0.81-0.88)**	0.60 (0.55-0.65)	**0.66 (0.61-0.72)**
		3	**0.83**	0.63	**0.66**	**0.81 (0.73-0.88)**	0.65 (0.52-0.78)	**0.71 (0.57-0.79)**	**0.81 (0.77-0.84)**	0.65 (0.60-0.69)	**0.71 (0.66-0.76)**
		5	**0.82**	0.65	**0.69**	**0.79 (0.73-0.85)**	0.69 (0.60-0.79)	**0.71 (0.61-0.78)**	**0.79 (0.74-0.83)**	0.68 (0.63-0.73)	**0.71 (0.65-0.76)**
		10	**0.8**	0.67	**0.73**	**0.79 (0.75-0.84)**	0.70 (0.65-0.75)	**0.75 (0.69-0.79)**	**0.78 (0.72-0.82)**	0.69 (0.63-0.74)	**0.73 (0.67-0.79)**
Coronary Heart Disease Death	MESA	2	**0.63**	0.63	**0.74**	**0.63 (0.35-0.75)**	0.63 (0.16-0.73)	**0.74 (0.65-0.89)**	**0.63 (0.56-0.70)**	0.63 (0.56-0.69)	**0.74 (0.66-0.81)**
		3	**0.68**	0.57	**0.67**	**0.73 (0.53-0.81)**	0.51 (0.30-0.73)	**0.61 (0.36-0.81)**	**0.73 (0.66-0.79)**	0.51 (0.44-0.58)	**0.61 (0.53-0.68)**
		5	**0.73**	0.58	0.53	**0.79 (0.68-0.85)**	0.59 (0.44-0.68)	**0.69 (0.52-0.84)**	**0.79 (0.72-0.84)**	0.59 (0.51-0.66)	**0.69 (0.61-0.76)**
		10	**0.76**	0.56	**0.6**	**0.77 (0.69-0.83)**	0.56 (0.46-0.64)	**0.67 (0.58-0.76)**	**0.75 (0.67-0.81)**	0.55 (0.47-0.64)	**0.65 (0.56-0.74)**
Incident OSA	WSC	5	**0.7**	**0.77**	0.48	**0.72 (0.65-0.77)**	**0.74 (0.69-0.79)**	0.53 (0.45-0.59)	**0.71 (0.63-0.78)**	**0.74 (0.67-0.81)**	0.51 (0.42-0.61)
Myocardial Infarction	MESA	1	**0.7**	0.54	**0.66**	**0.70 (0.51-0.97)**	0.54 (0.42-0.83)	**0.66 (0.48-0.96)**	**0.70 (0.67-0.74)**	0.54 (0.50-0.58)	**0.66 (0.62-0.70)**
		2	**0.63**	0.54	**0.61**	**0.59 (0.46-0.81)**	0.55 (0.40-0.72)	**0.58 (0.45-0.77)**	**0.59 (0.54-0.64)**	0.55 (0.49-0.60)	**0.57 (0.52-0.63)**
		3	**0.62**	0.55	**0.6**	**0.61 (0.50-0.76)**	0.55 (0.44-0.68)	**0.59 (0.49-0.75)**	**0.61 (0.56-0.66)**	0.55 (0.50-0.60)	**0.59 (0.53-0.65)**
		5	**0.63**	0.57	**0.61**	**0.62 (0.53-0.71)**	0.59 (0.50-0.68)	**0.61 (0.54-0.70)**	**0.61 (0.55-0.67)**	0.58 (0.52-0.64)	**0.61 (0.54-0.67)**
		10	**0.62**	0.57	**0.61**	**0.63 (0.57-0.70)**	0.58 (0.52-0.65)	**0.61 (0.55-0.67)**	**0.61 (0.53-0.68)**	0.57 (0.49-0.65)	**0.58 (0.49-0.67)**
Stroke	MESA	1	0.43	**0.57**	**0.57**	0.43 (0.25-0.61)	**0.57 (0.46-0.67)**	**0.57 (0.47-0.72)**	0.43 (0.40-0.46)	**0.57 (0.54-0.61)**	**0.57 (0.53-0.61)**
		2	0.46	**0.5**	**0.55**	**0.49 (0.33-0.62)**	0.42 (0.30-0.54)	**0.52 (0.40-0.64)**	0.48 (0.43-0.53)	0.42 (0.38-0.47)	**0.51 (0.45-0.58)**
		3	0.47	**0.5**	**0.55**	**0.51 (0.38-0.63)**	0.48 (0.37-0.59)	**0.54 (0.43-0.66)**	0.51 (0.46-0.57)	0.48 (0.43-0.54)	**0.54 (0.47-0.61)**
		5	0.52	**0.52**	**0.54**	**0.57 (0.47-0.66)**	0.56 (0.47-0.63)	**0.56 (0.50-0.62)**	0.56 (0.50-0.62)	0.56 (0.50-0.62)	**0.55 (0.48-0.62)**
		10	**0.55**	0.53	**0.55**	**0.62 (0.55-0.69)**	0.57 (0.50-0.63)	**0.57 (0.51-0.64)**	**0.60 (0.51-0.68)**	0.57 (0.48-0.65)	0.55 (0.45-0.65)

Table 5: SleepJEPA long-term outcomes predictive performance at different forecast lengths (independent testing). SleepJEPA+, SleepJEPA, and the baseline demographics age+sex model are reported. iAUC is the integral of the C/D AUC, up to that year. C-Index is the IPCW C-Index for the reported year. Bold, underlined indicates best performance and bold indicates second best performance. Results are for the independent test sets for available outcomes. 95% bootstrapped confidence intervals (n = 999 resamples) are reported for C/D AUC and C-Index.

at year 3, respectively. At a 5-year forecast, SleepJEPA+ improves performance in CV disease death, congestive heart failure, coronary heart disease death, cognitive decline, diabetes, OSA, and myocardial infarction with iAUC scores of 0.82, 0.80, 0.82, 0.78, 0.81, 0.86, and 0.80. At 10 and/or 15-year forecasts, SleepJEPA+ outperforms the demographics baseline for congestive heart failure, coronary heart disease death, cognitive decline, diabetes, hypertension, and myocardial infarction. The demographics baseline performed comparably for estimating angina, CV disease death, and stroke at 10- and 15-year forecasts. IBS is reported in Supplementary Table 4, and all models were calibrated well, with similar scores.

Independent test sets were evaluated for outcomes with additional data. On the MESA study for CV disease death, SleepJEPA+ outperforms the baseline demographics at all risk horizons, with a 10-year iAUC score of 0.80 compared to 0.67 for SleepJEPA and 0.73 for the baseline demographics model. Coronary heart disease death was also evaluated in the MESA study. SleepJEPA+ had a 10-year iAUC score of 0.76, compared to SleepJEPA (iAUC = 0.56) and the demographics baseline (iAUC = 0.60). OSA was assessed using the WSC dataset. SleepJEPA+ and SleepJEPA outperformed the demographics baseline at 5 years, achieving an iAUC score of 0.70 and 0.77, respectively. For myocardial infarction on the MESA dataset, SleepJEPA+ appears to increase predictive power at shorter risk horizons with a 5-year iAUC score of 0.63 compared to a baseline demographics model of 0.61. For stroke on the MESA dataset, no model achieved an AUC above 0.60, except for the 10-year C/D AUC score, where SleepJEPA+ reached a score of 0.62 (95% CI: 0.55 - 0.69) compared to 0.57 (0.51 - 0.64) for the baseline demographics model. C/D AUC curves for independent testing are illustrated in Extended Data Figure 5, and iAUC, C/D AUC, and IPCW C-Index are reported in Table 5. IBS scores were similar and are reported in Supplementary Table 5.

SleepJEPA is comparable in performance while utilizing fewer signals or demographic variables to other models. We compared SleepJEPA+ risk modeling to He et al. (He et al., 2025) and SleepFM (Thapa et al., 2026) at 5-year (He et al.) or 6-year (SleepFM) horizons on held-out SHHS data. Results are reported in Table 6. Compared to He et al., SleepJEPA+ improves performance for CV disease death, incident hypertension, and myocardial infarction. For congestive heart failure, He et al. had a higher AUC score of 0.85, compared to SleepJEPA+ with 0.84 (95% CI: 0.80 - 0.89). Compared to SleepFM, SleepJEPA+ matches or improves performance across angina, congestive heart failure, coronary heart disease death, myocardial infarction, and stroke. For CV disease death, SleepFM achieves a slightly higher AUC score of 0.88 (0.83 - 0.91) than SleepJEPA's 0.87 (0.81 - 0.93).

3.5 Correlations of Sleep Summary Measures with SleepJEPA Risk Estimates

To further understand outcome predictions, cumulative risk scores from SleepJEPA across 15 years were extracted for the SHHS held-out dataset. Cumulative risk scores at 1, 2, 3, 5, 10, and 15 were correlated with common polysomnogram features for angina, CV disease death, congestive heart failure, coronary heart disease death, cognitive decline, diabetes, hypertension, OSA, myocardial infarction, and stroke. Mean correlation results are reported in Figure 5, and per year heatmaps are shown in Supplementary Figure 3.

| | 6-Year AUC | | 6-Year C-Index | | 5-Year AUC | |
Outcome	SleepJEPA+	SleepFM	SleepJEPA+	SleepFM	SleepJEPA+	He et al.
Angina	**0.77 (0.71-0.83)**	0.76 (0.72-0.81)	**0.75 (0.66-0.82)**	0.73 (0.71–0.75)	0.76 (0.70-0.82)	-
Cardiovascular Disease Death	0.87 (0.81-0.93)	**0.88 (0.83-0.91)**	0.85 (0.77-0.91)	**0.86 (0.83–0.89)**	**0.85 (0.79-0.91)**	0.783
Congestive Heart Failure	**0.85 (0.81-0.89)**	**0.85 (0.82-0.88)**	**0.83 (0.77-0.87)**	**0.83 (0.81–0.86)**	0.84 (0.80-0.89)	**0.848**
Coronary Heart Disease Death	**0.87 (0.79-0.94)**	0.87 (0.82-0.92)	0.86 (0.78-0.92)	0.86 (0.82–0.89)	0.85 (0.74-0.93)	-
Incident Hypertension	-		-		**0.76 (0.68-0.83)**	0.597
Myocardial Infarction	**0.81 (0.74-0.86)**	0.78 (0.71-0.84)	**0.79 (0.71-0.85)**	0.75 (0.71–0.79)	0.82 (0.74-0.87)	0.711
Stroke	**0.86 (0.80-0.90)**	0.82 (0.76-0.87)	**0.84 (0.76-0.90)**	0.81 (0.76–0.85	0.85 (0.77-0.90)	-

Table 6: SleepJEPA long-term outcomes predictive performance compared to other models on held-out SHHS. SleepJEPA+ is compared to SleepFM (Thapa et al., 2026) at 6 years with AUC and C-Index metrics. SleepJEPA+ is also compared to He et al. at 5 years with AUC (He et al., 2025). Models reported all included demographics. Bold indicates the best performance. 95% bootstrapped confidence intervals (n = 999 resamples) are reported for AUC and C-Index (if available).

Figure 5: SleepJEPA representations predicted mean cumulative risk correlations across risk horizons (up to 15 years). The average Pearson correlation was calculated across available time horizons with normalized demographic and baseline PSG derived features. Correlations for each outcome are shown with 95% confidence intervals for the SHHS held-out test set and MrOS held-out test set (for cognitive decline).

Across all outcomes, age was a top 3 correlation with risk predictions, except for diabetes, cognitive decline, OSA, and myocardial infarction. Age was most correlated with angina risk predictions (r = 0.48 [95% CI: 0.46 - 0.49]). Sleep efficiency was negatively correlated across all outcomes and highest for CV outcomes, including angina, CV disease death, congestive heart failure, coronary heart disease death, myocardial infarction, and stroke. Average or minimum SpO2 was also negatively correlated for all outcomes except for cognitive decline, with a maximum for incident OSA (r = -0.41 [-0.46 - -0.36]). Obstructive and central AHI were positively correlated with risk predictions for congestive heart failure, coronary heart disease death, diabetes, and OSA, with a maximum of 0.41 (0.36 - 0.47) and 0.39 (0.34 - 0.44) for obstructive and central AHI for OSA. Stroke and cognitive decline had a low correlation with obstructive and central AHI. Arousal index followed a similar trend as obstructive and central AHI; however, this was more correlated with cognitive decline and less correlated with hypertension, myocardial infarction, and stroke. REM sleep time was modestly negatively correlated with angina, CV disease death, stroke, cognitive decline, and myocardial infarction. N1 sleep time was positively correlated with CV disease death (r = 0.2 [0.2 - 0.21]), coronary heart disease death (r = 0.16 [0.15 - 0.17]), and diabetes (r = 0.14 [0.11 - 0.17]). N2 sleep time was positively correlated with coronary heart disease death, angina, and myocardial infarction, and N3 sleep time was correlated with coronary heart disease death (r = -0.13 [-0.13 - -0.12]). Total sleep time was negatively correlated with all outcomes, with an absolute maximum of -0.27 (-0.28 - -0.26) for coronary heart disease death and the largest correlation for cognitive decline (r = -0.15 [-0.17 -

-0.12]). BMI was positively correlated with OSA, diabetes, hypertension, myocardial infarction, and coronary heart disease death, but not with other outcomes. ESS was not highly correlated with any outcome. See Supplementary Table 6 for all mean cumulative risk prediction correlations.

3.6 Survival modeling with SleepJEPA risk estimates

Survival curves for SleepJEPA+ for each outcome were plotted using the SHHS and MrOS held-out test sets. Results are shown in Figure 6. Independent test set results are shown in Extended Data Figure 6. SleepJEPA+ identifies quartiles of high, medium-high, medium-low, and low risk individuals at a 10-year horizon with modest separation for angina, CV disease death, congestive heart failure, coronary heart disease death, myocardial infarction, and stroke. Incident outcomes had more overlapping quartile confidence intervals. Diabetes had a crossover of curves with medium-high risk and high risk, potentially indicating poor calibration. On the independent test set, risk quartiles were maintained for CV disease death and coronary heart disease death. Additionally, risk quartile separation was notably better for OSA compared to the held-out test set, likely due to the larger distribution of time to events in the WSC dataset. For myocardial infarction and stroke, the higher risk quartile was more clearly separated, with more overlap for the lower quartiles.

3.7 Model Explainability

The integrated gradients method on SleepJEPA representations traced which representations contribute to predictions for each outcome. Using samples from the SHHS held-out test set and MrOS (for incident cognitive decline), attribution scores were calculated and visualized in Supplementary Figures 4-13. Per channel aggregated attributions showed that abdominal and/or thoracic RIP channels were a top 3 contributory signal to classifications for positive events for all outcomes, except coronary heart disease death, where ECG, chin EMG, and EEG had the highest attributions. Additionally, chin EMG was a common contributing channel for all outcomes, except for cognitive decline, where thoracic and abdominal RIP and SpO2 had the highest attributions. EOG and/or EEG had high attributions for congestive heart failure, coronary heart disease death, CV disease death, incident hypertension, and stroke. Incident OSA, CV disease death, and coronary heart disease death had the largest normalized attribution values, potentially indicating multiple channel-representations of relevance for risk estimation. While attributions may appear focused on specific channels, all outcomes have modest attributions across all signal channels. This may reflect SleepJEPA's encoder attention mechanism, which processes channels independently using learned channel-agnostic attention weights, potentially diluting channel-specific information in the representation space and distributing attribution across channels.

4 Discussion

We present SleepJEPA, the first joint embedding predictive architecture that learns foundational representations of at-home PSG signal data in the latent space. SleepJEPA was trained, validated, and tested on 422,035 hours of sleep signals from 55,518 studies. Notably, SleepJEPA can encode hPSG recordings of variable length (between 6 and 12 hours), enabling scalability and versatility for use in research, clinical, and home settings.

SleepJEPA's largest contribution is examining the relationship between sleep measured at-home and long-term disease risk. While two prior works have applied self-supervised learning of PSG signals for related tasks (He et al., 2025; Thapa et al., 2026), SleepJEPA advances the field by modeling discrete hazard risk for up to 15 years, independently training disease outcomes, testing disease outcomes on independent datasets, examining performance in relation to clinical features and survival, and utilizing solely at-home PSGs.

He et al. built a multichannel self-supervised model with at-home signal channels (ECG, EEG, and respiratory signals) to contrast CV disease outcome embeddings for risk estimation at 5 years using the SHHS dataset for training and WSC for independent validation (He et al., 2025). While He et al. independently builds logistic regression models for specific diseases, they fit a binary classification model per outcome and do not estimate risk with Cox proportional hazards or another survival method, potentially limiting performance, especially with censored data. Further, they limited their modeling to a 5-year risk horizon, which is insufficient for capturing the full spectrum of disease risk. Longer horizons are valuable for younger individuals with low short-term risk who may develop disease over time, while shorter horizons allow clinicians to identify older individuals at imminent risk.

Thapa et al. built SleepFM, a multichannel self-supervised model with in-lab PSG brain, cardiac, and respiratory channels, and showed that signal representations were predictive of age, sex, sleep staging, and a multilabel condition risk estimation task at 6 years with 1,041 disease outcomes (Thapa et al., 2026). They showed that these representations could be fine-tuned to the SHHS dataset with impressive performance, despite only pretraining for one epoch. Notably, SleepFM was not evaluated on independent test sets, limiting assessment of generalizability. As with He et al., risk

Figure 6: Survival curves at 10 years for all outcomes examining SleepJEPA+ risk quartiles on the SHHS held-out test set and MrOS held-out test set. Probabilities were calibrated using Platt scaling per model-outcome using the validation set prior to survival monitoring. 95% confidence intervals are displayed in bands.

estimation was confined to a 6-year horizon, which may be insufficient for capturing long-term disease trajectories across diverse age groups. SleepFM estimates risk with a multilabel Cox proportional hazards model; however, this multilabel task makes it difficult to determine which observations are predictive of labels given that patients present with multiple comorbidities and could confound results (Park et al., 2020). Additionally, as mentioned in the Methods, Cox proportional hazards modeling requires large batch sizes and proportional hazards, both of which were not discussed in SleepFM, especially when age effects vary over time.

SleepJEPA overcomes these limitations and illustrates the relationship between at-home sleep study signals and disease risk over time. SleepJEPA representations are more predictive at shorter time horizons, and age and sex hazard modeling enhances predictions for longer risk horizons. Additionally, SleepJEPA was independently tested on out of distribution datasets, and maintained impressive performance in CV disease death, coronary heart disease death, and incident OSA risk predictions at various horizons. For myocardial infarction and stroke, performance decreased, potentially due to differences in labeling definitions compared to the training set, prevalence, or time to event distributions (see Supplementary Table 3).

Across all outcomes, sleep disruptions and length are related to a multitude of conditions, including the ones examined in this study (Yang et al., 2024). Sleep feature correlations and attributions likely reflect these disruptions. However, identifying sleep features and attributions related to future disease via risk estimation helps detect potentially relevant clinical factors.

For CV and coronary heart disease death, SleepJEPA estimates reveal positive correlations between N1 sleep time, AHI, and arousal index, with high chin EMG signal attributions potentially indicating disrupted sleep, a known risk factor for CV disease, coronary heart disease, and mortality (Ai et al., 2024; Huang et al., 2025; Nagai et al., 2010). Congestive heart failure, myocardial infarction, and stroke risk estimations revealed high correlation with AHI and attributions in chin EMG and respiration signals. This supports previous research that has found heart failure as the top comorbidity with sleep disordered breathing (Khayat et al., 2013). ECG attributions were also high in myocardial infarction, coronary heart disease death, and incidental hypertension. While not all CV outcomes showed high ECG attributions, ECG signals combined with sleep stages are related to increased risk for myocardial infarction, stroke, and chronic heart failure (Manimaran et al., 2025). Interestingly, EOG attributions were high for congestive heart failure. While not traditionally thought of as distinguishing disordered breathing in sleep, recent works have shown EOG's ability to distinguish sleep stages (van Gorp et al., 2024) and identify sleep disorders (Jain and Ganesan, 2024). Additionally, it is possible they are reflecting a lack of sleep, given a negative correlation with sleep efficiency.

Angina and diabetes risk predictions followed similar patterns suggestive of breathing disturbances with high correlation with AHI and high attributions in respiratory channels. Notably, both shorter sleep (< 7 hours) and longer sleep (> 8 hours) individuals have been found to have a higher risk for grade 2 angina, with atypical (right-sided neck, or epigastric pain) angina manifesting in those with shorter sleep at higher odds (Alhaque Roomi et al., 2025). While we did see a positive correlation with N2 sleep time, total sleep time decreased, potentially suggesting that angina was more likely related to shorter duration of sleep and atypical type.

Incident cognitive decline and diabetes were the two primary outcomes to highlight the SpO2 channel in attributions. Hypoxemia has been studied extensively in relation to cognitive decline (Blackwell et al., 2015; Yaffe et al., 2011). A recent work examined specifically that during REM sleep, hypoxemia is a strong link for cerebral small vessel disease and dementia (Berisha et al., 2025). While attributions for SpO2 were high, correlations with oxygen saturation features were low. REM sleep was negatively correlated with the predictions, possibly suggesting that our model was capturing more complex features than just SpO2. Additionally, SleepJEPA appears to be identifying disturbances to oxygen saturation and EEG in those with diabetes with high attributions and correlation with SpO2 features. Works have shown hypoxemia during sleep increases blood glucose levels (SHINODA et al., 2018) and identified an EEG index of hyperglycemia (a coupling of NREM sleep spindles and slow oscillations) that SleepJEPA could be identifying (R et al., 2023). Importantly, OSA estimation had the highest attributions. Given that OSA was the only sleep disorder outcome, it shows a clearer picture between representations and the predictions and how age and sex are not necessarily good predictors for all outcomes, given the drastic performance differences.

Unsurprisingly, the demographics baseline, which includes age and sex, performs strongly. Age is well known to be the main risk factor for common diseases (Niccoli and Partridge, 2012), and older people are more likely to have sleep problems and disorders (Madan Jha, 2023; Tatineny et al., 2020). Despite the high performance of the demographics baseline, it appears that modeling both sleep representations and hazards has an additive effect, perhaps to help extract more specific features from representations related to age and sex during finetuning. Interestingly, it also seems that the age only model overfits the training cohort data, given the discernible improvement of SleepJEPA in the independent testing evaluations.

SleepJEPA also exhibits reliable performance in sleep staging, with modest improvement over a masked autoregression approach (PFTSleep (Fox et al., 2025a)), especially in stage N1 sleep and on independent evaluation datasets. This highlights the advantage of learning representations in the latent space via JEPA. Further, SleepJEPA's representations can estimate sleep stages with similar performance to other state-of-the-art models, while using frozen 3-second representations. While we aggregate to the traditional 30-second "sleep epoch" for comparison to other models, SleepJEPA's 3-second representations — to our knowledge the smallest input size used for sleep staging — could capture more nuanced staging information and warrant further exploration. Finally, we extensively evaluate SleepJEPA representations for sleep stage classification on three large independent datasets. Performance remains high for wake, N2, and REM sleep and is especially compelling for MrOS visit 2, which had the highest macro F1 score (69.4) among the independent test sets. Given that SleepJEPA was finetuned with MrOS visit 1 for sleep staging, high performance on MrOS visit 2 suggests that SleepJEPA could be quickly finetuned to specific clinic data to support longitudinal patient monitoring and standardization of sleep technician labeling.

In addition to sleep staging, SleepJEPA's representations appear to contain information related to daytime sleepiness and narcolepsy. SleepJEPA can estimate an MSLT score of 8 minutes or less (AUC = 0.64), an indicator for daytime sleepiness. When the daytime sleepiness model is independently tested to estimate type 1 narcolepsy, performance is similar (0.65), potentially indicating daytime sleepiness features are present in people with type 1 narcolepsy. When SleepJEPA's representations are finetuned to estimate narcolepsy, performance suggests that there are even stronger features indicative of narcolepsy (0.88), but those features are not all present in those with daytime sleepiness (0.56). Recent work has shown that objective daytime sleepiness is associated with a higher risk of all-cause mortality (Dai et al., 2025). For patients with OSA, this could be related to the pulse oximetry signal (included in SleepJEPA), which has been shown to help distinguish those who have objective daytime sleepiness (Kainulainen et al., 2020).

Our study has limitations. While we do show that SleepJEPA excels across a multitude of horizons, conditions, and independent testing sets, our sleep study cohorts are primarily older individuals who presented with a sleep problem and were evaluated via polysomnography. The need for additional data across diverse cohorts is key to further sleep prognostic models. Second, incident outcome data and MrOS angina, congestive heart failure, stroke, and myocardial infarction labels were acquired from survey responses potentially leading to less accurate labels or over-estimations of the time to event, which could imply performance is higher at longer risk horizons and lower at shorter risk horizons. Third, model explainability is inherently difficult with self-supervised deep learning approaches. While we kept signal channels separate during training and examined model attribution scores per-channel at each 3 second token, identifying clinically interpretable features on signal data was not performed and should be a point of future work. Finally, differences in outcome labeling, prevalence, and time to event distributions for each dataset could lead to varied performance. This may be exemplified in our independent testing, where performance decreased.

Overall, SleepJEPA demonstrates that at-home sleep signals can serve as a scalable, non-invasive window into long-term disease risk. Integrated alongside other clinical risk assessment tools, SleepJEPA has the potential to provide meaningful insight into patients' long-term health. Future work should explore combining SleepJEPA with other clinical features to further improve predictive performance, and investigate whether reduced signal sets, such as type III sleep signals and wearable devices, can maintain performance, lowering barriers to widespread clinical deployment.

5   Acknowledgments

This work was partially supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number R01HL175992 and the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR004420. Further, this work was supported in part through the computational and data resources and staff expertise provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai. Research reported in this publication was also supported by the Office of Research Infrastructure of the National Institutes of Health under award number S10OD026880 and S10OD030463. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The Sleep Heart Health Study (SHHS) was supported by National Heart, Lung, and Blood Institute cooperative agreements U01HL53916 (University of California, Davis), U01HL53931 (New York University), U01HL53934 (University of Minnesota), U01HL53937 and U01HL64360 (Johns Hopkins University), U01HL53938 (University of Arizona), U01HL53940 (University of Washington), U01HL53941 (Boston University), and U01HL63463 (Case Western Reserve University).

The Apnea Positive Pressure Long-term Efficacy Study (APPLES) was supported by the National Heart, Lung, and Blood Institute (U01HL68060).

The Multi-Ethnic Study of Atherosclerosis (MESA) Sleep Ancillary study was funded by NIH-NHLBI Association of Sleep Disorders with Cardiovascular Health Across Ethnic Groups (RO1 HL098433). MESA is supported by NHLBI funded contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by cooperative agreements UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 funded by NCATS.

The Wisconsin Sleep Cohort (WSC) Study was supported by the U.S. National Institutes of Health, National Heart, Lung, and Blood Institute (R01HL62252), National Institute on Aging (R01AG036838, R01AG058680), and the National Center for Research Resources (1UL1RR025011).

The National Heart, Lung, and Blood Institute provided funding for the ancillary MrOS Sleep Study, "Outcomes of Sleep Disorders in Older Men," under the following grant numbers: R01 HL071194, R01 HL070848, R01 HL070847, R01 HL070842, R01 HL070841, R01 HL070837, R01 HL070838, and R01 HL070839.

The Mignot Nature Communications (MNC) research was mostly supported by a grant from Jazz Pharmaceuticals to E.M. Additional funding came from: NIH grant R01HL62252 (to P.E.P.); Ministry of Science and Technology 2015CB856405 and National Foundation of Science of China 81420108002,81670087 (to F.H.); H. Lundbeck A/S, Lundbeck Foundation, Technical University of Denmark and Center for Healthy Aging, University of Copenhagen (to P.J. and H.B.D.S). Additional support was provided by the Klarman Family, Otto Mønsted, Stibo, Vera & Carl Johan Michaelsens, Knud Højgaards, Reinholdt W. Jorck and Hustrus and Augustinus Foundations (to A.N.O.).

The National Sleep Research Resource was supported by the National Heart, Lung, and Blood Institute (R24 HL114473, 75N92019R002).

The Human Sleep Project has received support from the Glenn Foundation and the American Federation of Aging Research (AFAR) through the 2018 Glenn / AFAR Award for Medical Research Breakthroughs in Gerontology (BIG) (2018), the American Academy of Sleep Medicine (AASM) through a 2019 Strategic Research Award, the National Institutes of Health (NIH) (R01NS102190, R01NS102574, R01NS107291, RF1AG064312, RF1NS120947, R01AG073410, R01HL161253, R01NS126282, R01AG073598), the National Science Foundation (NSF 2014431), and through the Henry and Allison McCance Center for Brain Health.

References

Jaquelini Betta Canever, Gabriela Zurman, Felipe Vogel, Daiana Vieira Sutil, Juliano Bergamaschine Mata Diz, Ana Lúcia Danielewicz, Bruno de Souza Moreira, Helena Iturvides Cimarosti, and Núbia Carelli Pereira de Avelar. Worldwide prevalence of sleep problems in community-dwelling older adults: A systematic review and meta-analysis. *Sleep Medicine*, 119:118–134, July 2024. ISSN 1389-9457. doi:10.1016/j.sleep.2024.03.040. URL https://www.sciencedirect.com/science/article/pii/S1389945724001448.

Vijay Kumar Chattu, Sateesh M. Sakhamuri, Raman Kumar, David Warren Spence, Ahmed S. BaHammam, and Seithikurippu R. Pandi-Perumal. Insufficient Sleep Syndrome: Is it time to classify it as a major noncommunicable disease? *Sleep Science*, 11(2):56–64, 2018a. ISSN 1984-0659. doi:10.5935/1984-0063.20180013. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056073/.

Vijay Kumar Chattu, Md. Dilshad Manzar, Soosanna Kumary, Deepa Burman, David Warren Spence, and Seithikurippu R. Pandi-Perumal. The Global Problem of Insufficient Sleep and Its Serious Public Health Implications. *Healthcare*, 7(1):1, December 2018b. ISSN 2227-9032. doi:10.3390/healthcare7010001. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473877/.

Diane C. Lim, Arezu Najafi, Lamia Afifi, Claudio LA Bassetti, Daniel J. Buysse, Fang Han, Birgit Högl, Yohannes Adama Melaku, Charles M. Morin, Allan I. Pack, Dalva Poyares, Virend K. Somers, Peter R. Eastwood, Phyllis C. Zee, and Chandra L. Jackson. The need to promote sleep health in public health agendas across the globe. *The Lancet Public Health*, 8(10):e820–e826, October 2023. ISSN 2468-2667. doi:10.1016/S2468-2667(23)00182-2. URL https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00182-2/fulltext.

Ketrell L McWhorter, Christine G Parks, Aimee A D'Aloisio, Darlynn M Rojo-Wissar, Dale P Sandler, and Chandra L Jackson. Traumatic childhood experiences and multiple dimensions of poor sleep among adult women. *Sleep*, 42(8):zsz108, August 2019. ISSN 0161-8105. doi:10.1093/sleep/zsz108. URL https://doi.org/10.1093/sleep/zsz108.

Yohannes Adama Melaku, Sarah Appleton, Amy C. Reynolds, Alexander M. Sweetman, David J. Stevens, Leon Lack, and Robert Adams. Association Between Childhood Behavioral Problems and Insomnia Symptoms in Adulthood.

JAMA Network Open, 2(9):e1910861, September 2019. ISSN 2574-3805. doi:10.1001/jamanetworkopen.2019.10861. URL https://doi.org/10.1001/jamanetworkopen.2019.10861.

Haitham A. Jahrami, Omar A. Alhaj, Ali M. Humood, Ahmad F. Alenezi, Feten Fekih-Romdhane, Maha M. AlRasheed, Zahra Q. Saif, Nicola Luigi Bragazzi, Seithikurippu R. Pandi-Perumal, Ahmed S. BaHammam, and Michael V. Vitiello. Sleep disturbances during the COVID-19 pandemic: A systematic review, meta-analysis, and meta-regression. *Sleep Medicine Reviews*, 62:101591, April 2022. ISSN 1087-0792. doi:10.1016/j.smrv.2022.101591. URL https://www.sciencedirect.com/science/article/pii/S1087079222000041.

Markku Partinen, Brigitte Holzinger, Charles M. Morin, Colin Espie, Frances Chung, Thomas Penzel, Christian Benedict, Courtney J. Bolstad, Jonathan Cedernaes, Rachel Ngan Yin Chan, Yves Dauvilliers, Luigi De Gennaro, Fang Han, Yuichi Inoue, Kentaro Matsui, Damien Leger, Ana Suely Cunha, Ilona Merikanto, Sergio Mota-Rolim, Michael Nadorff, Giuseppe Plazzi, Jules Schneider, Mariusz Sieminski, Yun-Kwok Wing, and Bjørn Bjorvatn. Sleep and daytime problems during the COVID-19 pandemic and effects of coronavirus infection, confinement and financial suffering: a multinational survey using a harmonised questionnaire. *BMJ Open*, 11(12):e050672, December 2021. ISSN 2044-6055, 2044-6055. doi:10.1136/bmjopen-2021-050672. URL https://bmjopen.bmj.com/content/11/12/e050672.

Adam V. Benjafield, Fatima H Sert Kuniyoshi, Atul Malhotra, Jennifer L. Martin, Charles M. Morin, Leonie F. Maurer, Peter A. Cistulli, Jean-Louis Pépin, and Emerson M. Wickwire. Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis. *Sleep Medicine Reviews*, 82:102121, August 2025. ISSN 1087-0792. doi:10.1016/j.smrv.2025.102121. URL https://www.sciencedirect.com/science/article/pii/S1087079225000747.

Adam V. Benjafield, Najib T. Ayas, Peter R. Eastwood, Raphael Heinzer, Mary S. M. Ip, Mary J. Morrell, Carlos M. Nunez, Sanjay R. Patel, Thomas Penzel, Jean-Louis Pépin, Paul E. Peppard, Sanjeev Sinha, Sergio Tufik, Kate Valentine, and Atul Malhotra. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *The Lancet. Respiratory Medicine*, 7(8):687–698, August 2019. ISSN 2213-2619. doi:10.1016/S2213-2600(19)30198-5.

Peige Song, Jing Wu, Jin Cao, Weidi Sun, Xiaoyu Li, Tianjing Zhou, Yaojia Shen, Xiao Tan, Xinxin Ye, Changzheng Yuan, Yajie Zhu, and Igor Rudan. The global and regional prevalence of restless legs syndrome among adults: A systematic review and modelling analysis. *Journal of Global Health*, 14:04113. ISSN 2047-2978. doi:10.7189/jogh.14.04113. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC11156251/.

Agnete Skovlund Dissing, Thea Otte Andersen, Liv Nielsen Nørup, Alice Clark, Miriam Nejsum, and Naja Hulvej Rod. Daytime and nighttime smartphone use: A study of associations between multidimensional smartphone behaviours and sleep among 24,856 Danish adults. *Journal of Sleep Research*, 30(6):e13356, 2021. ISSN 1365-2869. doi:10.1111/jsr.13356. URL https://onlinelibrary.wiley.com/doi/abs/10.1111/jsr.13356. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/jsr.13356.

Bastien Lechat, Jack Manners, Lucía Pinilla, Amy C. Reynolds, Hannah Scott, Daniel Vena, Sebastien Bailly, Josh Fitton, Barbara Toson, Billingsley Kaambwa, Robert J. Adams, Jean-Louis Pepin, Pierre Escourrou, Peter Catcheside, and Danny J. Eckert. Global warming may increase the burden of obstructive sleep apnea. *Nature Communications*, 16(1):5100, June 2025. ISSN 2041-1723. doi:10.1038/s41467-025-60218-1. URL https://www.nature.com/articles/s41467-025-60218-1.

Kelton Minor, Andreas Bjerre-Nielsen, Sigga Svala Jonasdottir, Sune Lehmann, and Nick Obradovich. Rising temperatures erode human sleep globally. *One Earth*, 5(5):534–549, May 2022. ISSN 25903322. doi:10.1016/j.oneear.2022.04.008. URL https://linkinghub.elsevier.com/retrieve/pii/S2590332222002093.

Evan D Chinoy, Joseph A Cuellar, Kirbie E Huwa, Jason T Jameson, Catherine H Watson, Sara C Bessman, Dale A Hirsch, Adam D Cooper, Sean P A Drummond, and Rachel R Markwald. Performance of seven consumer sleep-tracking devices compared with polysomnography. *Sleep*, 44(5):zsaa291, December 2020. ISSN 0161-8105. doi:10.1093/sleep/zsaa291. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120339/.

Cathy A. Goldstein, Richard B. Berry, David T. Kent, David A. Kristo, Azizi A. Seixas, Susan Redline, and M. Brandon Westover. Artificial intelligence in sleep medicine: background and implications for clinicians. *Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine*, 16(4):609–618, April 2020. ISSN 1550-9389. doi:10.5664/jcsm.8388. URL https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161463/.

Behrouz Jafari and Vahid Mohsenin. Polysomnography. *Clinics in Chest Medicine*, 31(2):287–297, June 2010. ISSN 0272-5231, 1557-8216. doi:10.1016/j.ccm.2010.02.005. URL https://www.chestmed.theclinics.com/article/S0272-5231(10)00028-6/abstract.

Atul Malhotra, Magdy Younes, Samuel T. Kuna, Ruth Benca, Clete A. Kushida, James Walsh, Alexandra Hanlon, Bethany Staley, Allan I. Pack, and Grace W. Pien. Performance of an Automated Polysomnography Scoring System Versus Computer-Assisted Manual Scoring. *Sleep*, 36(4):573. doi:10.5665/sleep.2548. URL `https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612255/`.

Marcel Braun, Steven Coughlin, and Hartmut Schneider. 1101 Long-term Trends in Utilization of Sleep Diagnostic Tests Among Medicare Beneficiaries. *Sleep*, 47(Supplement_1):A472–A473, May 2024a. ISSN 0161-8105. doi:10.1093/sleep/zsae067.01101. URL `https://doi.org/10.1093/sleep/zsae067.01101`.

Vaishnavi Kundel and Neomi Shah. Impact of Portable Sleep Testing. *Sleep medicine clinics*, 12(1):137–147, March 2017. ISSN 1556-407X. doi:10.1016/j.jsmc.2016.10.006. URL `https://pmc.ncbi.nlm.nih.gov/articles/PMC5458525/`.

Diana Vitazkova, Helena Kosnacova, Daniela Turonova, Erik Foltan, Martin Jagelka, Martin Berki, Michal Micjan, Ondrej Kokavec, Filip Gerhat, and Erik Vavrinsky. Transforming Sleep Monitoring: Review of Wearable and Remote Devices Advancing Home Polysomnography and Their Role in Predicting Neurological Disorders. *Biosensors*, 15(2), February 2025. ISSN 2079-6374. doi:10.3390/bios15020117. URL `https://www.mdpi.com/2079-6374/15/2/117`.

M. Braun, M. Stockhoff, M. Tijssen, S. Dietz-Terjung, S. Coughlin, and C. Schöbel. A Systematic Review on the Technical Feasibility of Home-Polysomnography for Diagnosis of Sleep Disorders in Adults. *Current Sleep Medicine Reports*, 10(2):276–288, June 2024b. ISSN 2198-6401. doi:10.1007/s40675-024-00301-z. URL `https://doi.org/10.1007/s40675-024-00301-z`.

Henri Korkalainen, Sami Nikkonen, Samu Kainulainen, Amit Krishna Dwivedi, Sami Myllymaa, Timo Leppänen, and Juha Töyräs. Self-Applied Home Sleep Recordings: The Future of Sleep Medicine. *Sleep Medicine Clinics*, 16(4):545–556, December 2021. ISSN 1556-407X, 1556-4088. doi:10.1016/j.jsmc.2021.07.003. URL `https://www.sleep.theclinics.com/article/S1556-407X(21)00055-2/abstract`.

Hyojin Lee, You Rim Choi, Hyun Kyung Lee, Jaemin Jeong, Joopyo Hong, Hyun-Woo Shin, and Hyung-Sin Kim. Explainable vision transformer for automatic visual sleep staging on multimodal PSG signals. *NPJ digital medicine*, 8(1):55, January 2025. ISSN 2398-6352. doi:10.1038/s41746-024-01378-0.

Samaneh Nasiri, Wolfgang Ganglberger, Thijs Nassi, Erik-Jan Meulenbrugge, Valdery Moura Junior, Manohar Ghanta, Aditya Gupta, Katie L. Stone, Magnus Ruud Kjaer, Oliver Sum-Ping, Emmanuel Mignot, Dennis Hwang, Lynn Marie Trotti, Gari D. Clifford, Umakanth Katwa, Haoqi Sun, Robert J. Thomas, and M. Brandon Westover. CAISR: achieving human-level performance in automated sleep analysis across all clinical sleep metrics. *Sleep*, 48(8):zsaf134, August 2025. ISSN 0161-8105. doi:10.1093/sleep/zsaf134. URL `https://pmc.ncbi.nlm.nih.gov/articles/PMC12341759/`.

Thijs E. Nassi, Wolfgang Ganglberger, Haoqi Sun, Abigail A. Bucklin, Siddharth Biswal, Michel J. A. M. van Putten, Robert J. Thomas, and M. Brandon Westover. Automated Scoring of Respiratory Events in Sleep With a Single Effort Belt and Deep Neural Networks. *IEEE transactions on bio-medical engineering*, 69(6):2094–2104, June 2022. ISSN 1558-2531. doi:10.1109/TBME.2021.3136753.

Alexander Neergaard Olesen, Poul Jørgen Jennum, Emmanuel Mignot, and Helge Bjarup Dissing Sorensen. Automatic sleep stage classification with deep residual networks in a mixed-cohort setting. *Sleep*, 44(1):zsaa161, January 2021. ISSN 0161-8105. doi:10.1093/sleep/zsaa161. URL `https://doi.org/10.1093/sleep/zsaa161`.

Mathias Perslev, Sune Darkner, Lykke Kempfner, Miki Nikolic, Poul Jørgen Jennum, and Christian Igel. U-Sleep: resilient high-frequency sleep staging. *npj Digital Medicine*, 4(1):1–12, April 2021. ISSN 2398-6352. doi:10.1038/s41746-021-00440-5. URL `https://www.nature.com/articles/s41746-021-00440-5`.

Huy Phan, Kristian P. Lorenzen, Elisabeth Heremans, Oliver Y. Chén, Minh C. Tran, Philipp Koch, Alfred Mertins, Mathias Baumert, Kaare B. Mikkelsen, and Maarten De Vos. L-SeqSleepNet: Whole-cycle Long Sequence Modeling for Automatic Sleep Staging. *IEEE Journal of Biomedical and Health Informatics*, 27(10):4748–4757, October 2023. ISSN 2168-2208. doi:10.1109/JBHI.2023.3303197. URL `https://ieeexplore.ieee.org/abstract/document/10210638`. Conference Name: IEEE Journal of Biomedical and Health Informatics.

Huy Phan, Kaare Mikkelsen, Oliver Y. Chén, Philipp Koch, Alfred Mertins, and Maarten De Vos. SleepTransformer: Automatic Sleep Staging With Interpretability and Uncertainty Quantification. *IEEE Transactions on Biomedical Engineering*, 69(8):2456–2467, August 2022a. ISSN 1558-2531. doi:10.1109/TBME.2022.3147187. Conference Name: IEEE Transactions on Biomedical Engineering.

Huy Phan, Oliver Y. Chén, Minh C. Tran, Philipp Koch, Alfred Mertins, and Maarten De Vos. XSleepNet: Multi-View Sequential Model for Automatic Sleep Staging. *IEEE Transactions on Pattern Analysis and Machine Intelligence*, 44(9):5903–5915, September 2022b. ISSN 1939-3539. doi:10.1109/TPAMI.2021.3070057. Conference Name: IEEE Transactions on Pattern Analysis and Machine Intelligence.

Hasan Zan and Abdulnasır Yildiz. Multi-task learning for arousal and sleep stage detection using fully convolutional networks. *Journal of Neural Engineering*, 20(5):056034, October 2023. ISSN 1741-2552. doi:10.1088/1741-2552/acfe3a. URL https://dx.doi.org/10.1088/1741-2552/acfe3a.

Bharath Ambale-Venkatesh, Xiaoying Yang, Colin O. Wu, Kiang Liu, W. Gregory Hundley, Robyn McClelland, Antoinette S. Gomes, Aaron R. Folsom, Steven Shea, Eliseo Guallar, David A. Bluemke, and João A. C. Lima. Cardiovascular Event Prediction by Machine Learning: The Multi-Ethnic Study of Atherosclerosis. *Circulation Research*, 121(9):1092–1101, October 2017. ISSN 1524-4571. doi:10.1161/CIRCRESAHA.117.311312.

Matthew P. Butler, Jeffery T. Emch, Michael Rueschman, Scott A. Sands, Steven A. Shea, Andrew Wellman, and Susan Redline. Apnea-Hypopnea Event Duration Predicts Mortality in Men and Women in the Sleep Heart Health Study. *American Journal of Respiratory and Critical Care Medicine*, 199(7):903–912, April 2019. ISSN 1535-4970. doi:10.1164/rccm.201804-0758OC.

Clémence Cavaillès, Meredith Wallace, Yue Leng, Katie L. Stone, Sonia Ancoli-Israel, and Kristine Yaffe. Multidimensional sleep profiles via machine learning and risk of dementia and cardiovascular disease. *Communications Medicine*, 5(1):306, July 2025. ISSN 2730-664X. doi:10.1038/s43856-025-01019-x. URL https://www.nature.com/articles/s43856-025-01019-x.

Zuzana Koscova, Ali Bahrami Rad, Samaneh Nasiri, Matthew A. Reyna, Reza Sameni, Lynn M. Trotti, Haoqi Sun, Niels Turley, Katie L. Stone, Robert J. Thomas, Emmanuel Mignot, Brandon Westover, and Gari D. Clifford. From sleep patterns to heart rhythm: Predicting atrial fibrillation from overnight polysomnograms. *Journal of Electrocardiology*, 86:153759, 2024. ISSN 1532-8430. doi:10.1016/j.jelectrocard.2024.153759.

Lulu Zhang, Huili Wu, Xiangyu Zhang, Xinfa Wei, Fengzhen Hou, and Yan Ma. Sleep heart rate variability assists the automatic prediction of long-term cardiovascular outcomes. *Sleep Medicine*, 67:217–224, March 2020. ISSN 1389-9457. doi:10.1016/j.sleep.2019.11.1259. URL https://www.sciencedirect.com/science/article/pii/S1389945719316466.

Shahab Haghayegh, Ruben Herzog, David A Bennett, Susan Redline, Kristine Yaffe, Katie L Stone, Agustin Ibáñez, and Kun Hu. Predicting future risk of developing cognitive impairment using ambulatory sleep EEG: Integrating univariate analysis and multivariate information theory approach. *Journal of Alzheimer's Disease*, page 13872877251319742, March 2025. ISSN 1387-2877. doi:10.1177/13872877251319742. URL https://doi.org/10.1177/13872877251319742.

Haoqi Sun, Sasha Milton, Yi Fang, Hash Brown Taha, Shreya Shiju, Robert J. Thomas, Wolfgang Ganglberger, Matthew P. Pase, Timothy Hughes, Shaun Purcell, Susan Redline, Katie L. Stone, Kristine Yaffe, M. Brandon Westover, and Yue Leng. Dementia Risk and Machine Learning-Derived Brain Age Index from Sleep Electroencephalography: A Pooled Cohort Analysis of Over 7,000 Individuals Across Five Community Cohorts, September 2025. URL https://www.medrxiv.org/content/10.1101/2025.09.21.25336255v1. ISSN: 3067-2007 Pages: 2025.09.21.25336255.

Andreas Brink-Kjaer, Eileen B. Leary, Haoqi Sun, M. Brandon Westover, Katie L. Stone, Paul E. Peppard, Nancy E. Lane, Peggy M. Cawthon, Susan Redline, Poul Jennum, Helge B. D. Sorensen, and Emmanuel Mignot. Age estimation from sleep studies using deep learning predicts life expectancy. *npj Digital Medicine*, 5(1):1–10, July 2022. ISSN 2398-6352. doi:10.1038/s41746-022-00630-9. URL https://www.nature.com/articles/s41746-022-00630-9.

Jens B. Stephansen, Alexander N. Olesen, Mads Olsen, Aditya Ambati, Eileen B. Leary, Hyatt E. Moore, Oscar Carrillo, Ling Lin, Fang Han, Han Yan, Yun L. Sun, Yves Dauvilliers, Sabine Scholz, Lucie Barateau, Birgit Hogl, Ambra Stefani, Seung Chul Hong, Tae Won Kim, Fabio Pizza, Giuseppe Plazzi, Stefano Vandi, Elena Antelmi, Dimitri Perrin, Samuel T. Kuna, Paula K. Schweitzer, Clete Kushida, Paul E. Peppard, Helge B. D. Sorensen, Poul Jennum, and Emmanuel Mignot. Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. *Nature Communications*, 9(1):5229, December 2018. ISSN 2041-1723. doi:10.1038/s41467-018-07229-3. URL https://www.nature.com/articles/s41467-018-07229-3.

Bastien Lechat, Camila Hirotsu, Sarah Appleton, Magdy Younes, Robert J Adams, Andrew Vakulin, Kristy Hansen, Branko Zajamsek, Gary Wittert, Peter Catcheside, Raphael Heinzer, and Danny J Eckert. A novel EEG marker predicts perceived sleepiness and poor sleep quality. *Sleep*, 45(5):zsac051, May 2022a. ISSN 0161-8105, 1550-9109. doi:10.1093/sleep/zsac051. URL https://academic.oup.com/sleep/article/doi/10.1093/sleep/zsac051/6542375.

Bastien Lechat, Kristy L. Hansen, Yohannes Adama Melaku, Andrew Vakulin, Gorica Micic, Robert J. Adams, Sarah Appleton, Danny J. Eckert, Peter Catcheside, and Branko Zajamsek. A Novel Electroencephalogram-derived Measure of Disrupted Delta Wave Activity during Sleep Predicts All-Cause Mortality Risk. *Annals of the American Thoracic Society*, 19(4):649–658, April 2022b. ISSN 2329-6933. doi:10.1513/AnnalsATS.202103-315OC. URL https://www.atsjournals.org/doi/10.1513/AnnalsATS.202103-315OC.

Matthew Christensen, Milos Vukadinovic, Neal Yuan, and David Ouyang. Vision–language foundation model for echocardiogram interpretation. *Nature Medicine*, pages 1–8, April 2024. ISSN 1546-170X. doi:10.1038/s41591-024-02959-y. URL https://www.nature.com/articles/s41591-024-02959-y.

Zhi Huang, Federico Bianchi, Mert Yuksekgonul, Thomas J. Montine, and James Zou. A visual–language foundation model for pathology image analysis using medical Twitter. *Nature Medicine*, pages 1–10, August 2023. ISSN 1546-170X. doi:10.1038/s41591-023-02504-3. URL https://www.nature.com/articles/s41591-023-02504-3.

DongAo Ma, Jiaxuan Pang, Michael B. Gotway, and Jianming Liang. A fully open AI foundation model applied to chest radiography. *Nature*, 643(8071):488–498, July 2025. ISSN 1476-4687. doi:10.1038/s41586-025-09079-8. URL https://www.nature.com/articles/s41586-025-09079-8.

Jinxi Xiang, Xiyue Wang, Xiaoming Zhang, Yinghua Xi, Feyisope Eweje, Yijiang Chen, Yuchen Li, Colin Bergstrom, Matthew Gopaulchan, Ted Kim, Kun-Hsing Yu, Sierra Willens, Francesca Maria Olguin, Jeffrey J. Nirschl, Joel Neal, Maximilian Diehn, Sen Yang, and Ruijiang Li. A vision–language foundation model for precision oncology. *Nature*, pages 1–10, January 2025. ISSN 1476-4687. doi:10.1038/s41586-024-08378-w. URL https://www.nature.com/articles/s41586-024-08378-w.

Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, Yanbo Xu, Mu Wei, Wenhui Wang, Shuming Ma, Furu Wei, Jianwei Yang, Chunyuan Li, Jianfeng Gao, Jaylen Rosemon, Tucker Bower, Soohee Lee, Roshanthi Weerasinghe, Bill J. Wright, Ari Robicsek, Brian Piening, Carlo Bifulco, Sheng Wang, and Hoifung Poon. A whole-slide foundation model for digital pathology from real-world data. *Nature*, 630(8015):181–188, June 2024. ISSN 1476-4687. doi:10.1038/s41586-024-07441-w. URL https://www.nature.com/articles/s41586-024-07441-w.

Kai Zhang, Rong Zhou, Eashan Adhikarla, Zhiling Yan, Yixin Liu, Jun Yu, Zhengliang Liu, Xun Chen, Brian D. Davison, Hui Ren, Jing Huang, Chen Chen, Yuyin Zhou, Sunyang Fu, Wei Liu, Tianming Liu, Xiang Li, Yong Chen, Lifang He, James Zou, Quanzheng Li, Hongfang Liu, and Lichao Sun. A generalist vision–language foundation model for diverse biomedical tasks. *Nature Medicine*, 30(11):3129–3141, November 2024. ISSN 1546-170X. doi:10.1038/s41591-024-03185-2. URL https://www.nature.com/articles/s41591-024-03185-2.

Yukun Zhou, Mark A. Chia, Siegfried K. Wagner, Murat S. Ayhan, Dominic J. Williamson, Robbert R. Struyven, Timing Liu, Moucheng Xu, Mateo G. Lozano, Peter Woodward-Court, Yuka Kihara, Andre Altmann, Aaron Y. Lee, Eric J. Topol, Alastair K. Denniston, Daniel C. Alexander, and Pearse A. Keane. A foundation model for generalizable disease detection from retinal images. *Nature*, 622(7981):156–163, October 2023. ISSN 1476-4687. doi:10.1038/s41586-023-06555-x. URL https://www.nature.com/articles/s41586-023-06555-x.

Hubert Banville, Omar Chehab, Aapo Hyvärinen, Denis-Alexander Engemann, and Alexandre Gramfort. Uncovering the structure of clinical EEG signals with self-supervised learning. *Journal of Neural Engineering*, 18(4):046020, March 2021. ISSN 1741-2552. doi:10.1088/1741-2552/abca18. URL https://dx.doi.org/10.1088/1741-2552/abca18.

Benjamin Fox, Joy Jiang, Sajila Wickramaratne, Patricia Kovatch, Mayte Suarez-Farinas, Neomi A Shah, Ankit Parekh, and Girish N Nadkarni. A foundational transformer leveraging full night, multichannel sleep study data accurately classifies sleep stages. *Sleep*, page zsaf061, March 2025a. ISSN 0161-8105. doi:10.1093/sleep/zsaf061. URL https://doi.org/10.1093/sleep/zsaf061.

Zhengxiao He, Huayu Li, Geng Yuan, William D S Killgore, Stuart F Quan, Chen X Chen, and Ao Li. Multimodal cardiovascular risk profiling using self-supervised learning of polysomnography. *SLEEPJ*, page zsaf371, November 2025. ISSN 0161-8105, 1550-9109. doi:10.1093/sleep/zsaf371. URL https://academic.oup.com/sleep/advance-article/doi/10.1093/sleep/zsaf371/8342286.

Mattson Ogg and William G. Coon. Self-Supervised Transformer Model Training for a Sleep-EEG Foundation Model. In *2024 46th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)*, pages 1–6, July 2024. doi:10.1109/EMBC53108.2024.10782281. URL https://ieeexplore.ieee.org/abstract/document/10782281. ISSN: 2694-0604.

Rahul Thapa, Magnus Ruud Kjaer, Bryan He, Ian Covert, Hyatt Moore IV, Umaer Hanif, Gauri Ganjoo, M. Brandon Westover, Poul Jennum, Andreas Brink-Kjaer, Emmanuel Mignot, and James Zou. A multimodal sleep foundation model for disease prediction. *Nature Medicine*, pages 1–11, January 2026. ISSN 1546-170X. doi:10.1038/s41591-025-04133-4. URL https://www.nature.com/articles/s41591-025-04133-4.

Weining Weng, Yang Gu, Shuai Guo, Yuan Ma, Zhaohua Yang, Yuchen Liu, and Yiqiang Chen. Self-supervised Learning for Electroencephalogram: A Systematic Survey. *ACM Comput. Surv.*, 57(12):317:1–317:38, July 2025. ISSN 0360-0300. doi:10.1145/3736574. URL https://dl.acm.org/doi/10.1145/3736574.

Mahmoud Assran, Quentin Duval, Ishan Misra, Piotr Bojanowski, Pascal Vincent, Michael Rabbat, Yann LeCun, and Nicolas Ballas. Self-Supervised Learning from Images with a Joint-Embedding Predictive Architecture, April 2023. URL http://arxiv.org/abs/2301.08243. arXiv:2301.08243 [cs].

Sehun Kim. Learning General Representation of 12-Lead Electrocardiogram with a Joint-Embedding Predictive Architecture, December 2024. URL http://arxiv.org/abs/2410.08559. arXiv:2410.08559 [cs].

Kuba Weimann and Tim O. F. Conrad. Self-supervised pre-training with joint-embedding predictive architecture boosts ECG classification performance. *Computers in Biology and Medicine*, 196:110809, September 2025. ISSN 0010-4825. doi:10.1016/j.compbiomed.2025.110809. URL https://www.sciencedirect.com/science/article/pii/S0010482525011606.

Li Jing, Pascal Vincent, Yann LeCun, and Yuandong Tian. Understanding Dimensional Collapse in Contrastive Self-supervised Learning, April 2022. URL http://arxiv.org/abs/2110.09348. arXiv:2110.09348 [cs].

Erik Xie, Wyatt Chang, Raquel Rodriguez Martinez, and Brandon Ballinger. JETS: A Self-Supervised Joint Embedding Time Series Foundation Model for Behavioral Data in Healthcare. October 2025. URL https://openreview.net/forum?id=QqQDjLgHab.

Benjamin Fox, Dung T. Hoang, Joy Jiang, Pushkala Jayaraman, Ankit Parekh, Girish N. Nadkarni, and Ankit Sakhuja. PhysioJEPA: Joint Embedding Representations of Physiological Signals for Real Time Risk Estimation in the Intensive Care Unit. November 2025b. URL https://openreview.net/forum?id=bdXsfrNaGY.

Yuqi Nie, Nam H. Nguyen, Phanwadee Sinthong, and Jayant Kalagnanam. A Time Series is Worth 64 Words: Long-term Forecasting with Transformers. In *The Eleventh International Conference on Learning Representations*, 2023. URL https://openreview.net/forum?id=Jbdc0vTOcol.

Yuandong Tian, Xinlei Chen, and Surya Ganguli. Understanding self-supervised Learning Dynamics without Contrastive Pairs, October 2021. URL http://arxiv.org/abs/2102.06810. arXiv:2102.06810 [cs].

Randall Balestriero and Yann LeCun. LeJEPA: Provable and Scalable Self-Supervised Learning Without the Heuristics, November 2025. URL http://arxiv.org/abs/2511.08544. arXiv:2511.08544 [cs].

Aviv Goldbart, Paul Peppard, Laurel Finn, Chad M. Ruoff, Jodi Barnet, Terry Young, and Emmanuel Mignot. Narcolepsy and Predictors of Positive MSLTs in the Wisconsin Sleep Cohort. *Sleep*, 37(6):1043–1051, June 2014. ISSN 0161-8105. doi:10.5665/sleep.3758. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC4015378/.

Michael F. Gensheimer and Balasubramanian Narasimhan. A scalable discrete-time survival model for neural networks. *PeerJ*, 7:e6257, January 2019. ISSN 2167-8359. doi:10.7717/peerj.6257. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC6348952/.

Travers Ching, Xun Zhu, and Lana X. Garmire. Cox-nnet: An artificial neural network method for prognosis prediction of high-throughput omics data. *PLoS Computational Biology*, 14(4):e1006076, April 2018. ISSN 1553-734X. doi:10.1371/journal.pcbi.1006076. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC5909924/.

Jared L. Katzman, Uri Shaham, Alexander Cloninger, Jonathan Bates, Tingting Jiang, and Yuval Kluger. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. *BMC Medical Research Methodology*, 18:24, February 2018. ISSN 1471-2288. doi:10.1186/s12874-018-0482-1. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC5828433/.

Jérôme Lambert and Sylvie Chevret. Summary measure of discrimination in survival models based on cumulative/dynamic time-dependent ROC curves. *Statistical Methods in Medical Research*, 25(5):2088–2102, October 2016. ISSN 1477-0334. doi:10.1177/0962280213515571.

E. Graf, C. Schmoor, W. Sauerbrei, and M. Schumacher. Assessment and comparison of prognostic classification schemes for survival data. *Statistics in Medicine*, 18(17-18):2529–2545, September 1999. ISSN 0277-6715. doi:10.1002/(sici)1097-0258(19990915/30)18:17/18<2529::aid-sim274>3.0.co;2-5.

Hajime Uno, Tianxi Cai, Michael J. Pencina, Ralph B. D'Agostino, and L. J. Wei. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. *Statistics in Medicine*, 30(10):1105–1117, May 2011. ISSN 1097-0258. doi:10.1002/sim.4154.

Mukund Sundararajan, Ankur Taly, and Qiqi Yan. Axiomatic attribution for deep networks. In *Proceedings of the 34th International Conference on Machine Learning - Volume 70*, ICML'17, pages 3319–3328, Sydney, NSW, Australia, August 2017. JMLR.org.

Huy Phan, Fernando Andreotti, Navin Cooray, Oliver Y. Chén, and Maarten De Vos. SeqSleepNet: End-to-End Hierarchical Recurrent Neural Network for Sequence-to-Sequence Automatic Sleep Staging. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, 27(3):400–410, March 2019. ISSN 1534-4320, 1558-0210. doi:10.1109/TNSRE.2019.2896659. URL http://arxiv.org/abs/1809.10932. arXiv:1809.10932 [cs, eess, stat].

Emadeldeen Eldele, Zhenghua Chen, Chengyu Liu, Min Wu, Chee-Keong Kwoh, Xiaoli Li, and Cuntai Guan. An Attention-Based Deep Learning Approach for Sleep Stage Classification With Single-Channel EEG. *IEEE Transactions on Neural Systems and Rehabilitation Engineering*, 29:809–818, 2021. ISSN 1558-0210. doi:10.1109/TNSRE.2021.3076234. URL https://ieeexplore.ieee.org/abstract/document/9417097. Conference Name: IEEE Transactions on Neural Systems and Rehabilitation Engineering.

Alexander Neergaard Olesen, Poul Jørgen Jennum, Paul E. Peppard, Emmanuel Jean-Marie Mignot, and Helge Bjarup Dissing Sørensen. Deep residual networks for automatic sleep stage classification of raw polysomnographic waveforms. *2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)*, pages 1–4, 2018. URL https://api.semanticscholar.org/CorpusID:52945281.

Laurence A. F. Park, Yi Guo, and Jesse Read. Assessing the Multi-labelness of Multi-label Data. In Ulf Brefeld, Elisa Fromont, Andreas Hotho, Arno Knobbe, Marloes Maathuis, and Céline Robardet, editors, *Machine Learning and Knowledge Discovery in Databases*, pages 164–179, Cham, 2020. Springer International Publishing. ISBN 978-3-030-46147-8. doi:10.1007/978-3-030-46147-8_10.

Chao Yang, Peijing Yan, Xueyao Wu, Wenqiang Zhang, Huijie Cui, Li Zhang, Zhengxing Xu, Shanshan Peng, Mingshuang Tang, Yutong Wang, Lin Chen, Yanqiu Zou, Yunjie Liu, Min Zhang, Xunying Zhao, Jinyu Xiao, Chenghan Xiao, Ling Zhang, Yuqin Yao, Jiayuan Li, Zhenmi Liu, Chunxia Yang, Xia Jiang, and Ben Zhang. Associations of sleep with cardiometabolic risk factors and cardiovascular diseases: An umbrella review of observational and mendelian randomization studies. *Sleep Medicine Reviews*, 77:101965, October 2024. ISSN 1532-2955. doi:10.1016/j.smrv.2024.101965.

Sizhi Ai, Shuo Ye, Guohua Li, Yue Leng, Katie L. Stone, Min Zhang, Yun-Kwok Wing, Jihui Zhang, and Yannis Yan Liang. Association of Disrupted Delta Wave Activity During Sleep With Long-Term Cardiovascular Disease and Mortality. *Journal of the American College of Cardiology*, 83(17):1671–1684, April 2024. ISSN 0735-1097. doi:10.1016/j.jacc.2024.02.040. URL https://www.sciencedirect.com/science/article/pii/S0735109724004844.

Tianyi Huang, Sina Kianersi, Heming Wang, Kaitlin S. Potts, Raymond Noordam, Tamar Sofer, Martin K. Rutter, and Susan Redline. Sleep Duration Irregularity and Risk for Incident Cardiovascular Disease in the UK Biobank. *Journal of the American Heart Association*, 14(15):e040027, August 2025. doi:10.1161/JAHA.124.040027. URL https://www.ahajournals.org/doi/10.1161/JAHA.124.040027.

Michiaki Nagai, Satoshi Hoshide, and Kazuomi Kario. Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature. *Current Cardiology Reviews*, 6(1):54–61, February 2010. ISSN 1573-403X. doi:10.2174/157340310790231635. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC2845795/.

Rami Khayat, Roy Small, Lisa Rathman, Steven Krueger, Becky Gocke, Linda Clark, Laura Yamokoski, and William T. Abraham. Sleep Disordered Breathing in Heart Failure: Identifying and Treating an Important but Often Unrecognized Comorbidity in Heart Failure Patients. *Journal of cardiac failure*, 19(6):431–444, June 2013. ISSN 1071-9164. doi:10.1016/j.cardfail.2013.04.005. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC3690313/.

Gouthamaan Manimaran, Sadasivan Puthusserypady, Helena Dominguez, and Jakob E. Bardram. Cardiovascular Risk Assessment via Sleep Patterns and ECG-Based Biological Age Estimation. *Journal of Clinical Medicine*, 14 (10):3339, May 2025. ISSN 2077-0383. doi:10.3390/jcm14103339. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC12112499/.

Hans van Gorp, Merel M. van Gilst, Sebastiaan Overeem, Sylvie Dujardin, Angelique Pijpers, Bregje van Wetten, Pedro Fonseca, and Ruud J. G. van Sloun. Single-channel EOG sleep staging on a heterogeneous cohort of subjects with sleep disorders. *Physiological Measurement*, 45(5), May 2024. ISSN 1361-6579. doi:10.1088/1361-6579/ad4251.

Ritika Jain and Ramakrishnan Angarai Ganesan. Effective diagnosis of sleep disorders using EEG and EOG signals. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference*, 2024:1–4, July 2024. ISSN 2694-0604. doi:10.1109/EMBC53108.2024.10782470.

Maslahuddin HA Alhaque Roomi, Nehal Eid, and Aayush Visaria. Association Between Sleep Duration and Angina Characteristics in United States Adults. *American Journal of Medicine Open*, 14:100109, June 2025. ISSN 2667-0364. doi:10.1016/j.ajmo.2025.100109. URL https://pmc.ncbi.nlm.nih.gov/articles/PMC12282262/.

Terri Blackwell, Kristine Yaffe, Alison Laffan, Susan Redline, Sonia Ancoli-Israel, Kristine E. Ensrud, Yeonsu Song, Katie L. Stone, and the Osteoporotic Fractures in Men Study Group. Associations Between Sleep-Disordered Breathing, Nocturnal Hypoxemia, and Subsequent Cognitive Decline in Older Community-Dwelling Men: The Osteoporotic Fractures in Men Sleep Study. *Journal of the American Geriatrics Society*, 63(3):453–461, 2015. ISSN 1532-5415. doi:10.1111/jgs.13321. URL https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.13321. _eprint: https://agsjournals.onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.13321.

Kristine Yaffe, Alison M Laffan, Stephanie Litwack Harrison, Susan Redline, Adam P Spira, Kristine E Ensrud, Sonia Ancoli-Israel, and Katie L Stone. Sleep disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. *JAMA : the journal of the American Medical Association*, 306(6):613–619, August 2011. ISSN 0098-7484. doi:10.1001/jama.2011.1115. URL `https://pmc.ncbi.nlm.nih.gov/articles/PMC3600944/`.

Destiny E. Berisha, Batool Rizvi, Miranda G. Chappel-Farley, Nicholas Tustison, Lisa Taylor, Abhishek Dave, Negin S. Sattari, Ivy Y. Chen, Kitty K. Lui, John C. Janecek, David B. Keator, Ariel B. Neikrug, Ruth M. Benca, Michael A. Yassa, and Bryce A. Mander. Association of Hypoxemia Due to Obstructive Sleep Apnea With White Matter Hyperintensities and Temporal Lobe Changes in Older Adults. *Neurology*, 104(11):e213639, June 2025. ISSN 1526-632X. doi:10.1212/WNL.0000000000213639.

MINORI SHINODA, TADASHI YAMAKAWA, RIKA SAKAMOTO, JUN SUZUKI, KENICHIRO TAKAHASHI, and YASUO TERAUCHI. Analysis of the Effect of the Lowest SpO2 on Nocturnal Blood Glucose Fluctuation in Type 2 Diabetes Measured by WatchPAT and Continuous Glucose Monitoring. *Diabetes*, 67(Supplement_1):1664–P, July 2018. ISSN 0012-1797. doi:10.2337/db18-1664-P. URL `https://doi.org/10.2337/db18-1664-P`.

Vallat R, Shah Vd, and Walker Mp. Coordinated human sleeping brainwaves map peripheral body glucose homeostasis. *Cell reports. Medicine*, 4(7), July 2023. ISSN 2666-3791. doi:10.1016/j.xcrm.2023.101100. URL `https://pubmed.ncbi.nlm.nih.gov/37421946/`.

Teresa Niccoli and Linda Partridge. Ageing as a risk factor for disease. *Current biology: CB*, 22(17):R741–752, September 2012. ISSN 1879-0445. doi:10.1016/j.cub.2012.07.024.

Vibha Madan Jha. The prevalence of sleep loss and sleep disorders in young and old adults. *Aging Brain*, 3:100057, January 2023. ISSN 2589-9589. doi:10.1016/j.nbas.2022.100057. URL `https://www.sciencedirect.com/science/article/pii/S2589958922000299`.

Prathusha Tatineny, Fariha Shafi, Ashraf Gohar, and Abid Bhat. Sleep in the Elderly. *Missouri Medicine*, 117(5): 490–495, 2020. ISSN 0026-6620. URL `https://pmc.ncbi.nlm.nih.gov/articles/PMC7723148/`.

Yanyuan Dai, Alexandros N Vgontzas, Baixin Chen, Le Chen, Jun Wu, Dandan Zheng, and Yun Li. Objective, but not subjective, daytime sleepiness predicts mortality in obstructive sleep apnea. *Sleep*, page zsaf138, May 2025. ISSN 0161-8105. doi:10.1093/sleep/zsaf138. URL `https://doi.org/10.1093/sleep/zsaf138`.

Samu Kainulainen, Juha Töyräs, Arie Oksenberg, Henri Korkalainen, Isaac O. Afara, Akseli Leino, Laura Kalevo, Sami Nikkonen, Natan Gadoth, Antti Kulkas, Sami Myllymaa, and Timo Leppänen. Power spectral densities of nocturnal pulse oximetry signals differ in OSA patients with and without daytime sleepiness. *Sleep Medicine*, 73:231–237, September 2020. ISSN 1389-9457. doi:10.1016/j.sleep.2020.07.015. URL `https://www.sciencedirect.com/science/article/pii/S1389945720303166`.

A   Extended Data

Outcome	Dataset	Positive Cases (%)	Negative Cases (%)	Median Days to Event (IQR)	Split
Angina	SHHS	359 (11.3%)	2820 (88.7%)	1644.9 (674.5-2452.5)	Training/Validation/Test
	MrOS	290 (12.0%)	2136 (88.0%)	1302.0 (453.0-1468.8)	Training/Validation/Test
Cardiovascular Disease Death	SHHS	355 (7.1%)	4655 (92.9%)	2506.9 (1575.5-3492.5)	Training/Validation/Test
	MrOS	747 (29.7%)	1772 (70.3%)	3828.4 (2507.5-5197.5)	Training/Validation/Test
	MESA	116 (5.7%)	1937 (94.3%)	2455.1 (1609.0-3324.3)	Independent Test
Congestive Heart Failure	SHHS	612 (12.2%)	4398 (87.8%)	2023.4 (972.0-3064.5)	Training/Validation/Test
	MrOS	239 (8.9%)	2442 (91.1%)	2174.2 (987.5-3874.0)	Training/Validation/Test
Coronary Heart Disease Death	SHHS	232 (4.6%)	4778 (95.4%)	2464.8 (1582.5-3414.0)	Training/Validation/Test
	MESA	53 (2.6%)	2000 (97.4%)	2449.9 (1369.0-3306.0)	Independent Test
Incident Cognitive Decline	MrOS	179 (6.6%)	2516 (93.4%)	1868.7 (514.5-3727.0)	Training/Validation/Test
Incident Diabetes	SHHS	99 (4.1%)	2344 (95.9%)	1919.2 (1846.0-1969.0)	Training/Validation/Test
	MrOS	143 (5.6%)	2395 (94.4%)	1882.9 (974.0-2709.0)	Training/Validation/Test
	WSC	44 (6.8%)	606 (93.2%)	1743.2 (730.5-2556.8)	Independent Test
Incident Hypertension	SHHS	590 (26.4%)	1647 (73.6%)	1651.3 (1750.0-1958.0)	Training/Validation/Test
	MrOS	270 (12.3%)	1924 (87.7%)	2241.2 (1269.0-3783.0)	Training/Validation/Test
Incident OSA	SHHS	252 (11.3%)	1973 (88.7%)	1901.5 (1841.8-1952.0)	Training/Validation/Test
	MrOS	143 (18.5%)	631 (81.5%)	2370.0 (2190.5-2522.5)	Training/Validation/Test
	WSC	122 (20.6%)	471 (79.4%)	2218.4 (1461.0-2922.0)	Independent Test
Myocardial Infarction	SHHS	357 (7.1%)	4653 (92.9%)	2074.2 (1111.0-3008.0)	Training/Validation/Test
	MrOS	257 (10.9%)	2101 (89.1%)	1726.5 (519.0-2482.0)	Training/Validation/Test
	MESA	84 (4.2%)	1926 (95.8%)	1903.9 (1081.5-2650.0)	Independent Test
Stroke	SHHS	286 (5.7%)	4724 (94.3%)	1774.5 (678.2-2600.5)	Training/Validation/Test
	MrOS	240 (8.8%)	2497 (91.2%)	1358.1 (438.5-1526.8)	Training/Validation/Test
	MESA	70 (3.5%)	1949 (96.5%)	1718.6 (871.3-2517.0)	Independent Test

Table 1: Long-term disease risk distributions for finetuning. Outcomes were provided by the study cohort datasets. "Incident" outcomes were calculated manually from follow up visits, since the baseline sleep study. Training, validation, and held-out testing followed identical splitting ratios for all outcomes: 72%, 8%, 20%, respectively.

Figure 1: SleepJEPA Context Encoder. During JEPA training, tokenized patches of signal data are randomly selected as targets for prediction. Targets are masked and only context tokens are passed through the context encoder to generate context representations.

Figure 2: SleepJEPA Target Encoder. During JEPA training, the target encoder receives the full input without masking, creating context and target representations. Note that the target encoder is identical to the context encoder, but its weights lag the context encoder weights and are updated by exponentially weighted moving average after each batch.

Figure 3: SleepJEPA Predictor. During JEPA training, the context representations are combined with per channel, learnable mask tokens and then passed through a predictor network (a smaller network, compared to the context and target encoders). The predictions are then compared to the target encoders output, after subsetting the outputs to the targets. The two are compared via an MSE loss function.

Figure 4: Attentive Finetuning Head. The attentive head pools patches across all channels with a full cross attention block into a single vector per channel. Following, the channel vectors are passed through a final prediction head, which is task dependent.

Figure 5: C/D AUC plots for independent test sets for available outcomes, up to 15 years. SleepJEPA+, SleepJEPA, and the baseline demographics models are reported. All models used MESA as an independent test set, except for incident OSA, which used WSC. 95% bootstrapped confidence intervals (n = 999 resamples) are shaded for each model.

Figure 6: Survival curves at 10 years for all independent testing outcomes examining SleepJEPA+ risk quartiles on the MESA or WSC (for incident OSA) independent test sets. Probabilities were calibrated using Platt scaling per model-outcome using the validation set prior to survival monitoring. 95% confidence intervals are displayed in bands.